Greater access to medicines and health technologies for those who need them
Greater access to medicines and health technologies for those who need them
Table of contents

04 FOREWORD
06 MESSAGE FROM UNITAID’S EXECUTIVE DIRECTOR
08 OUR IMPACT
10 2022 AT-A-GLANCE
12 KEY FEATURES OF OUR LICENCES
14 MPP’S LICENCES (2010 – 2022)
16 MedsPaL AND VaxPaL
18 INFECTIOUS DISEASES: MPP’s voluntary licensing system saves even more lives across the world
32 NOVEL MEDICAL TECHNOLOGIES: MPP’s exciting move into a new area with the potential for life-changing medicines
40 NON-COMMUNICABLE DISEASES: MPP signs first-ever cancer licence for low- and middle-income countries
42 COVID-19: new licence agreements demonstrate MPP’s readiness for future pandemics
52 mRNA TECHNOLOGY TRANSFER PROGRAMME: MPP helps to ensure long-term regional health security
58 2022 EVENTS AND ACTIVITIES
62 FOCUS ON PARTNERSHIP
64 MPP’S VISION, MISSION AND CORE VALUES
66 FOCUS ON THE FUTURE: MPP’S STRATEGY 2023-2025
70 FOCUS ON FUNDERS
72 GOVERNANCE
76 FINANCIAL REPORT

ACRONYMS AND ABBREVIATIONS

AIDS     Acquired Immune Deficiency Syndrome
AfroCAB  African Community Advisory Boards
ART      Antiretroviral Therapy
ARVs     Antiretrovirals
AVAC     AIDS Vaccine Advocacy Coalition
AWCPAB   African Women’s Community Prevention Accountability Board
CSIC     Spanish National Research Council
C-TAP    COVID-19 Technology Access Pool
DAAs     Direct Acting Antivirals
DAC      Dacatasvir
DALYs    Disability-Adjusted Life Years
DTG      Dolutegravir
EAG      Expert Advisory Group
EML      Model List of Essential Medicines
FDC      Fixed-Dose Combination
HCV      Hepatitis C Virus
HIV      Human Immunodeficiency Virus
LA       Long Acting
LATs     Long-Acting Therapeutics
LCs      Low-Income Countries
LMICs    Low- and Middle-Income Countries
MDR-TB   Multidrug Resistant TB
MPP      Medicines Patent Pool
NCDs     Non-Communicable Diseases
PPR      Pandemic Preparedness and Response
PEP      Pre-Exposure Prophylaxis
SAP      Scientific Advisory Panel
SDC      Swiss Agency for Development and Cooperation
TB       Tuberculosis
WHO      World Health Organization
Foreword: Marie-Paule Kieny and Charles Gore

The Medicines Patent Pool (MPP) is pleased to present its annual report for the year 2022. This year marked a significant period of growth, change, learning, and commitment for the organisation.

2022: A YEAR OF GROWTH

In 2022, MPP experienced substantial growth across various dimensions. Notably, we expanded our portfolio of signed licences, reaching a total of 34 licences with originator companies. This growth was driven by breakthrough agreements in long-acting formulations, including cabotegravir with ViiV Healthcare and Medincell technology for malaria. Additionally, we achieved a significant milestone in the fight against COVID-19 by signing a license for ensitrelvir fumaric acid with Japanese company Shionogi.

MPP also demonstrated remarkable progress in addressing non-communicable diseases (NCDs) through a license agreement with Novartis for nilotinib. This expansion of licences further solidified our commitment to improving healthcare access globally.

Furthermore, MPP fostered growth by engaging with a higher number of generic manufacturers. By June 2022, we collaborated with 58 manufacturers across 16 low- and middle-income countries, providing access to essential medicines at affordable prices. Although the number of manufacturers has decreased since then due to sublicences ending, it is essential to acknowledge the wide reach we achieved in enabling generic production.

Moreover, MPP experienced an expansion in the number of partners and collaborators, which allowed us to leverage expertise, resources, and support for our mission. The mRNA Technology Transfer Programme also witnessed notable growth in funding, enabling us to enhance our capabilities in this crucial area.

A YEAR OF CHANGE, LEARNING, COMMITMENT

2022 brought about significant changes and learnings for MPP. The world began to transition away from the devastating impact of the COVID-19 pandemic, allowing us to reconnect with people globally through events and meetings. This shift in focus from lockdowns and high death tolls reinforced our commitment to never letting such a crisis occur again. We must maintain our vigilance, share knowledge, and collaborate to be better prepared for future pandemics.

The Government of Indonesia, as President of the G20, recognised the vital role of MPP in building global health resilience and response capacity against future pandemic threats. Additionally, the World Trade Organization acknowledged MPP as the best source of information on COVID-19 vaccine patents, highlighting our expertise and commitment to transparency.

A YEAR TO LOOK AHEAD: MPP STRATEGIC DIRECTION

In collaboration with the Board, MPP dedicated time to reviewing priorities and establishing its strategic direction for 2023-2025. This new strategy focuses on five important goals that will guide our work in the coming years with the following three targets:

- Establish 10 new licences
- Support 10 technology transfers
- Develop 5 new products

A YEAR OF PARTNERSHIP

MPP acknowledges that all its achievements are only made possible through strong partnerships and collaboration. Governments, international organisations, civil society, experts, NGOs, researchers, the originator industry and generic manufacturers have all played crucial roles in our work. All of you, together with our Board, our expert advisors, our funders and Unitaid, make us what we are – an organisation that delivers affordable medicines and health technologies in low- and middle-income countries.
Message from Unitaid’s Executive Director

Together we save lives, with more than 30 million people on HIV treatment; we save time, by speeding up the global health response; and we save money, by shaving billions of dollars off the cost of health products.

MPP and Unitaid work hand in glove to ensure people in low and middle-income countries have access to highly effective new treatments and health technologies. We are united in our commitment to universal health coverage and determined to be well prepared for any pandemic that may strike in the future.

The COVID-19 pandemic was a shocking reminder that we are still far from bridging a very wide gap in equitable and affordable access to health products in low and middle-income countries.

With closely aligned strategies to guide our work, there is a great deal MPP and Unitaid can do to narrow the treatment gap in the coming years. MPP and Unitaid can make a huge difference in securing early licensing of drugs and building the foundations for broad-based generic markets for pharmaceutical products. We must back up sustainability of supply with product registration, demand generation and market shaping.

We also need to enlist the support of G7 countries to provide incentives and ask pharmaceutical companies to issue voluntary licences to MPP for their products and to commit support for technology transfer, when it is called for, on a broader country base in case of future pandemics.

Ensuring the world is ready to respond to any future pandemic will require capable and well-equipped manufacturers located in numerous locations with the capacity and commitment to produce quality-assured products fast and at affordable prices.

In the interest of equity, we need to build a consensus on public investments in R&D to include a public access requirement from the outset that is driven by public health needs. Such a requirement would mean that any product that is the result of public R&D should be made available automatically, rather than subject to negotiations with the product originator after the product has already been launched. In this way we can give meaning to a G7 commitment to accelerate R&D for medical countermeasures to address pandemics and health challenges such as anti-microbial resistance. Access policies should be an integral part of the innovation pathway.

Access can be broadened by supporting technologies that offer greater autonomy for people in healthcare, for example, through use of self-tests or tools, such as long-acting formulations that require less frequent intervention by a medical practitioner. Approaches such as these can improve access and outcomes by creating a virtuous circle.

Better and faster access to health technologies is essential to advance Universal Health Coverage. It is the only way to overcome glaring inequalities and strengthen pandemic preparedness.
Our Impact

MPP’S VOLUNTARY LICENCES HAVE ENABLED BROAD ACCESS TO THE BEST QUALITY-ASSURED, AFFORDABLE TREATMENTS

This has not only saved lives, but money too, in the form of lower costs for national governments and other procurers of medicines.

By December 2022

- MPP signed 36 different licences for health technologies
- Established partnerships with 58 manufacturing partners across 16 countries
- 25 products have been developed or supplied by MPP licensees

MODELLING THE IMPACT OF OUR WORK

Since 2021 MPP has focused on country-level impact, contrasting MPP’s contribution with alternative scenarios in which key WHO-recommended medicines would not have been available through MPP licences. The methodology evaluates the role of MPP licences in supporting expanded generic competition with the resulting effect on reducing drug prices and encouraging increased uptake with beneficial health and economic outcomes.

By December 2022

- UPTAKE OF MPP-LICENSED PRODUCTS: 34.69 billion doses of treatment supplied by MPP licensees
- COST SAVINGS: 1.5 billion USD of actual financial savings made by the international community by accessing MPP-licensed products
- DEATHS AVERTED: 27,000 death averted brought by increased access to optimal products recommended by WHO
2022 at-a-glance

**JANUARY**
- 20 JANUARY: 27 generic manufacturers sign agreements with MPP to produce low-cost versions of COVID-19 antiviral medication molnupiravir for supply in 105 low- and middle-income countries.
- 20 MAY: MPP joins ATOM, a new global coalition to increase access to, and the use of, essential cancer medicines in low- and middle-income countries.

**FEBRUARY**
- 3 FEBRUARY: Afrigen signs grant agreement with MPP to establish a technology transfer hub for COVID-19 mRNA vaccines.

**MARCH**
- 17 MARCH: 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries.
- 22 MARCH: Update: Ukrainian company Darnitsa signs sublicence agreement with MPP bringing to 36 the number of generic manufacturers to produce generic versions of Pfizer’s oral COVID-19 treatment.

**APRIL**
- 19 APRIL: MPP and WHO announce names of 15 programme partners that will work with the mRNA Technology Transfer Programme and receive technology transfer and training.

**MAY**
- 12 MAY: WHO and MPP announce agreement with the US National Institutes of Health (NIH) for 11 COVID-19 health technologies.
- 20 MAY: MPP joins ATOM, a new global coalition to increase access to, and the use of, essential cancer medicines in low- and middle-income countries.

**JUNE**
- 13 JUNE: GAP-f paediatric-DTG Implementation Considerations for National Programmes published.

**JULY**
- 28 JULY: MPP and ViiV Healthcare sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine, CAB-LA.

**SEPTEMBER**
- 13 SEPTEMBER: MPP and MedinCell sign licence agreement for mdc-STM, an investigational long-acting injectable formulation to fight malaria transmission.

**OCTOBER**
- 4 OCTOBER: MPP and Shionogi sign licence agreement for COVID-19 oral antiviral treatment candidate to increase access in low- and middle-income countries.
- 12 OCTOBER: MPP announces its newly-established and fully independent mRNA Scientific Advisory Committee.
- 20 OCTOBER: MPP signs licence agreement with Novartis to increase access to nilotinib for the treatment of chronic myeloid leukaemia. This is the first ever public health-oriented voluntary licence agreement for a cancer medicine.

**NOVEMBER**
- 28 NOVEMBER: Lancet Global Health publishes MPP’s paper on expanding access to biotherapeutics in low- and middle-income countries through public health non-exclusive voluntary intellectual property licensing.

**DECEMBER**
- 1 DECEMBER: More than 100 low- and middle-income countries have now received the WHO-recommended treatment for HIV thanks to access-oriented voluntary licensing agreements with ViiV Healthcare.
- 25 DECEMBER: Hetero’s nirmatrelvir/ritonavir COVID-19 product is approved by WHO-PQ, one of 18 COVID-19 products filed in 2022. This was the first filing and subsequent approval under the MPP nirmatrelvir licence; approval took place in record time, just 165 days after filing.
Key features of MPP’s licences

The terms and conditions of MPP licences seek to improve treatment options for the broadest number of people living in low- and middle-income countries.

Every licence is negotiated on a case-by-case basis with each patent holder.
MPP’s licences 2010 - 2022

For the past 12 years, MPP has applied its voluntary licensing and patent pooling model to secure more affordable access in low- and middle-income countries for life-saving medicines and health technologies.

In 2022, we signed four voluntary licensing agreements for the following products:

**cabotegravir (CAB)** LA for HIV PrEP with ViiV Healthcare;

An extended-release depot of **ivermectin**, as a community level malaria vector control tool, using Medincell’s BEPO® LA platform;

**nilotinib** for the treatment of myeloid leukaemia with Novartis;

**ensitrelvir fumaric acid** an oral antiviral to combat COVID-19, with Shionogi.

---

**abacavir (ABC) paediatric** – part of the WHO-preferred treatments for children or neonates

**atazanavir (ATV)** – part of the WHO-preferred second-line treatments for adults and children

**bictegravir (BIC)** – an HIV integrase inhibitor approved by the U.S. Food and Drug Administration in 2018 as part of a single tablet regimen

**cobicistat (COBI)** – a CYP3A inhibitor used as pharmacokinetic booster, which increases the exposure to a number of antiretrovirals (ARVs) and potentially other drugs

**COVID-19 serological antibody diagnostic test** – ELISA antibody technology

**daclatasvir (DAC)** – part of the WHO-recommended pan-genotypic regimen (in combination with sofosbuvir) for the treatment of chronic hepatitis C

**dolutegravir adult (DTG)** – part of the WHO-recommended preferred first- and second-line regimens for adults

**dolutegravir paediatric (DTG)** – part of the WHO-recommended preferred first- and second-line regimens for children and infants of at least four weeks of age and weighing at least three kilograms

**eloctregravir (EVR)** – approved for use in children and adults as part of fixed-dose combinations

**emtricitabine (FTC)** – part of WHO-recommended first- and second-line treatments for children and adults and for HIV PrEP

**glecaprevir/pibrentasvir (G/P)** – WHO-recommended pan-genotypic treatment for chronic hepatitis C

**long-acting injectable (LAI) HIV drug combination technology** – a technology with the potential to transform the WHO-recommended daily oral dosage of TLD (tenofovir/lamivudine/dolutegravir) for HIV treatment into a subcutaneous monthly injection

**long-acting technologies for HCV, TB, and malaria treatment** – technologies that could provide optimal doses of medicines for malaria chemoprophylaxis, TB prevention, and HCV cure

**lopinavir, ritonavir (LPV/r)** – part of WHO-recommended first and second-line regimens for adults

**lopinavir, ritonavir (LPV/r) paediatric** – part of WHO-recommended first-line regimen and preferred second-line regimen for children

**molnupiravir (MOL)** – WHO-recommended oral COVID-19 antiviral medicine

**nimodipine** – oral COVID-19 antiviral treatment to be taken in combination with low dose ritonavir

**patents-related to darunavir (DRV)** – MPP’s first licence signed with the U.S. National Institutes of Health; darunavir/ritonavir (r) is recommended by WHO as part of alternative second-line regimen for adults

**raltegravir (RAL) paediatric** – recommended by WHO as preferred first-line treatment for newborns, and alternative first-line options for children under special circumstances

**ravidasvir (RAV)** – an investigational drug for chronic hepatitis C as part of a combination treatment with sofosbuvir. The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia granted a conditional registration in 2021.

**solid drug nanoparticle technology** – a technology that reformulates poorly soluble and insoluble drugs into water dispersible formulations to improve delivery into the body, thereby reducing its oral dosage

**suzetoside** – an investigational drug for tuberculosis

**tenofovir alafenamide (TAF)** – WHO-recommended as an alternative first-line HIV treatment option in children; TAF is also approved for the treatment of chronic hepatitis B

**tenofovir disoproxil fumarate (TDF)** – WHO-recommended as a preferred first- and second-line HIV treatment for adults and as alternative first-line for children. It is also WHO-recommended for HIV PrEP and for the treatment of chronic hepatitis B infection.

---

COVID-19  |  HIV  |  Hepatitis C  |  Tuberculosis  |  Long-Acting Therapeutics
MedsPaL and VaxPaL

As part of MPP’s core mission to improve patent transparency, MPP has created a suite of patent information tools and licences database.

IN OCTOBER 2016, MPP LAUNCHED MedsPaL

This has become the world’s leading tool on the patent and licensing status of essential medicines in low- and middle-income countries.

While the database was initially meant to focus on three diseases only (HIV, HCV and Tuberculosis), its remit was expanded in 2018 to cover all patented medicines in WHO EML. MedsPaL was further expanded in 2020 to provide patent information on treatments being tested for COVID-19.

By the end of 2022 the database includes 5,544 national patent applications

96 international applications and had searchable information on 13 vaccines in 117 countries (covering both high-income countries and low- and middle-income countries)

To date the database includes 16,000 patents or patent applications and 70 licences covering 143 priority medicines and 291 formulations, in more than 130 low- and middle-income countries

VaxPaL WAS LAUNCHED IN JUNE 2021

Building on 10 years of MPP’s experience in mapping patents on key essential medicines to track and provide patent information on COVID-19 vaccines, the patent information on COVID-19 vaccines was compiled for the purpose of providing greater transparency on patents relating to key COVID-19 vaccines and focuses primarily (though not exclusively) on patents filed by the entities that have developed each vaccine. VaxPaL was released in a fully searchable online format in December 2021.

To date the database includes 16,000 patents or patent applications and 70 licences covering 143 priority medicines and 291 formulations, in more than 130 low- and middle-income countries

By the end of 2022 the database includes 5,544 national patent applications

96 international applications and had searchable information on 13 vaccines in 117 countries (covering both high-income countries and low- and middle-income countries)

VaxPaL WAS LAUNCHED IN JUNE 2021

Building on 10 years of MPP’s experience in mapping patents on key essential medicines to track and provide patent information on COVID-19 vaccines, the patent information on COVID-19 vaccines was compiled for the purpose of providing greater transparency on patents relating to key COVID-19 vaccines and focuses primarily (though not exclusively) on patents filed by the entities that have developed each vaccine. VaxPaL was released in a fully searchable online format in December 2021.
Infectious diseases

**MPP’S VOLUNTARY LICENSING SYSTEM SAVES EVEN MORE LIVES ACROSS THE WORLD**

Tackling infectious diseases has always been at the heart of MPP’s work. Great strides have been taken since our inception in 2010, and 2022 saw a significant continuation of this progress. Our voluntary licensing system has provided much greater access to life-saving drugs for people living with HIV and hepatitis; we are confident this model will be equally successful for other communicable diseases, including COVID-19.

**Paving the way for greater access to HIV treatment**

There can be no greater sign of MPP’s commitment to people and affected communities in low- and middle-income countries than our measures to help combat HIV. Each year sees approximately 1.5 million new HIV infections worldwide, most of which occur in countries with limited medical and financial resources. Women and adolescent girls are disproportionately affected in sub-Saharan Africa, with six in seven new HIV infections among adolescent girls aged 15–19 years.

![Image of two women]

**MORE AFFORDABLE MPP-LICENSED HIV PRODUCTS**

The greater prevalence of MPP-licensed HIV generic medicines meant that these medicines became even more affordable in low- and middle-income countries.

A total of 12 new generic versions of MPP-licensed HIV products were approved by a ‘Stringent Regulatory Authority’ (SRA) in 2022.

Furthermore, MPP-enabled HIV products have now been sold in 128 out of a possible 146 countries where those products are available for sale. This means that coverage for people living with HIV for these products now stands at 99.4 per cent, well above our target figure.

![Image of a woman in a rural setting]

**MPP’s continuing focus on HIV led to significant breakthroughs in 2022.**

**The average yearly treatment cost of HIV treatment across low- and middle-income countries using MPP-licensed generics’ product for HIV**

USD 106.60

**The average yearly treatment cost using innovators’ product**

USD 923.87

This means the average absolute difference is equivalent to a reduction in price of 88.5%.

EXPANDING OUR FOCUS ON CHILDREN

We’re delighted that our focus on children’s health is now paying dividends. A generic version of the preferred WHO-recommended paediatric HIV formulation – abacavir/lamivudine/dolutegravir (ABC/3TC/DTG), a fixed dose combination – was filed for the first time. Submitted by Cipla with both the US Food and Drug Administration (USFDA) and WHO-PQ in the second half of 2022, this could eventually see immeasurable benefits for children living with HIV with easy to take treatment options. This complements our existing focus on children’s needs.

In 2022, MPP-enabled generic versions of child-friendly DTG 10mg tablets were sold in 66 countries, which means that 38 more countries were supplied by MPP licensees than in 2021. This covers 31.35 per cent of low- and middle-income country children on antiretroviral treatment.

In 2022, MPP-enabled generic versions of child-friendly DTG 10mg tablets were sold in 66 countries, which means that 38 more countries were supplied by MPP licensees than in 2021. This covers 31.35 per cent of low- and middle-income country children on antiretroviral treatment.

A CLOSER LOOK: TLD

TLD is a generic HIV combination available in low- and middle-income countries

Containing tenofovir disoproxil, lamivudine and dolutegravir, it is more potent and durable than other treatments as it features a higher drug-resistance barrier and suppresses viral load more quickly. Over 80 per cent of people in low- and middle-income countries on first line antiretroviral treatment now take TLD in a single pill a day.

MPP’s manufacturing partners developed TLD for supply in low-and middle-income countries thanks to the agreements negotiated between MPP and ViiV Healthcare in 2014 and 2021. By 2021 the fixed-dose combination of TLD in a single dosage – developed by MPP’s manufacturing partners – was already delivering 20 million people. The number of low- and middle-income countries receiving the WHO-preferred TLD treatment for HIV passed the milestone of 100 countries in 2022. Eleven of MPP’s generic manufacturing licensees have now supplied more than 726 million packs of TLD, which means that it is now the most widely used HIV regimen in the world.

TLD treatment has been a game changer for those living with HIV. It’s a very effective and well-tolerated combination that contributes to suppressing the virus and reducing transmission. The partnership with ViiV Healthcare demonstrates beyond doubt that MPP’s public health licensing mechanism works very effectively and that affordable access to the best new treatments is possible for people across low- and middle-income countries.

WHAT OUR PARTNERS SAY

Having access to high-quality low-cost essential medicines is fundamental for people living in low- and middle-income countries, such as India. TLD is a great example of how, in just a few years, and thanks to agreements between the originator company and MPP, this brilliant innovative treatment was developed by our generic companies and delivered to those in need in the world. I applaud the fact that people living with HIV in more than 100 low- and middle-income countries can now access this treatment.

MERCY ANNASPORANI IS THE DIRECTOR OF INDIA’S PANEER HIV AIDS POSITIVE WOMEN NETWORK

Georgia was part of the bulk of countries receiving the first shipments of generic TLD towards the end of 2019. That is what prompted our government to transition all people living with HIV to TLD as first line treatment. People in my country can now afford this best-in-class treatment that is easy to take, and very well tolerated. This shows that innovation can be accessible to everyone and I’m very glad we’ve reached the 100 country-mark for this product.

MAKA GOGIA IS PROGRAMS DIRECTOR FOR THE GEORGIAN HARM REDUCTION NETWORK

Indonesia received its first supplies of TLD in 2020 in the midst of the COVID-19 pandemic. We had been wanting to access this product for months and two years on, we are glad to report that the treatment holds its promises: no side effects, better adherence, light pill burden. People living with HIV deserve access to innovation no matter where they live and, today we can celebrate this great milestone of 100 countries being supplied with TLD, including Indonesia.

ADITYA WARDHANA IS EXECUTIVE DIRECTOR OF INDONESIA’S AIDS COALITION

UPPER MIDDLE-INCOME COUNTRIES ALSO REAP BENEFITS

We have also continued to focus on upper middle-income countries. Smooth implementation of the DTG licence has taken place in Azerbaijan, Belarus, Kazakhstan and Malaysia. Across these four countries, guidelines have been updated, registrations have been completed and procurements have expanded. These moves have all led to a welcome increase in uptake.

Most important of all, the growing number of procurements means that the prices of generic products are falling. As always, MPP-led collaboration between governments, civil society and communities, as well as coordinated work with generic companies and procurement agencies played a major part in progressing licence implementation.
HIV TREATMENT:
KEY FACTS AND STATS FOR 2022

In 2022, 12 new generic versions of MPP-licensed HIV products received approval from a stringent regulatory authority (SRA). This included the first SRA approvals received by an MPP licensee for dolutegravir/lamivudine (DTG/3TC), alafenamide (TAF) 25mg and alafenamide/emtricitabine (TAF/FTC). Three of the approvals represented a first SRA approval received by an MPP generic partner for the product in question.

The first ever filing by a generic manufacturer of the preferred WHO-endorsed paediatric formulation was for abacavir/lamivudine/dolutegravir (ABC/3TC/DTG).

For the first time in 2022 MPP licensees supplied:
- DTG 50mg to Kazakhstan, Vietnam, Tunisia, Belize, Malaysia, Mauritania and the Seychelles
- TLD for Belarus, Tunisia, Barbados and Micronesia
- ABC/3TC/DTG adult for Central African Republic, Ukraine, Equatorial Guinea and Fiji
- TAF/FTC/DTG for El Salvador, Mali, Guatemala, Nicaragua, Senegal, Armenia and the Syrian Arab Republic

The average price reduction for MPP-enabled HIV products stands at 88%.

With TLD going to more countries in 2022 18.6% more people living with HIV have access to at least two MPP licenced products.

MPP-enabled products are now used by over 30M people living with HIV.

For the first time in 2022 supplied with TLD by MPP licensees in 2022

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PEOPLE LIVING WITH HIV</th>
<th>TLD (Packs of 30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>7,300,000</td>
<td>43 M</td>
</tr>
<tr>
<td>Uganda</td>
<td>1,300,000</td>
<td>20 M</td>
</tr>
<tr>
<td>Tanzania</td>
<td>1,600,000</td>
<td>19 M</td>
</tr>
<tr>
<td>Mozambique</td>
<td>1,900,000</td>
<td>16 M</td>
</tr>
<tr>
<td>Malawi</td>
<td>930,000</td>
<td>13 M</td>
</tr>
<tr>
<td>Nigeria</td>
<td>1,800,000</td>
<td>13 M</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>1,200,000</td>
<td>12 M</td>
</tr>
<tr>
<td>Zambia</td>
<td>1,300,000</td>
<td>12 M</td>
</tr>
<tr>
<td>Kenya</td>
<td>1,400,000</td>
<td>12 M</td>
</tr>
<tr>
<td>India</td>
<td>2,300,000</td>
<td>10 M</td>
</tr>
</tbody>
</table>

supplied with DTG 50mg by MPP licensees in 2022

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PEOPLE LIVING WITH HIV</th>
<th>DTG 50 mg (Packs of 30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>7,300,000</td>
<td>8 M</td>
</tr>
<tr>
<td>India</td>
<td>2,300,000</td>
<td>3 M</td>
</tr>
<tr>
<td>Malawi</td>
<td>930,000</td>
<td>505K</td>
</tr>
<tr>
<td>Thailand</td>
<td>520,000</td>
<td>504K</td>
</tr>
<tr>
<td>Mozambique</td>
<td>1,900,000</td>
<td>502K</td>
</tr>
<tr>
<td>Zambia</td>
<td>1,300,000</td>
<td>445K</td>
</tr>
<tr>
<td>Nigeria</td>
<td>1,800,000</td>
<td>423K</td>
</tr>
<tr>
<td>Tanzania</td>
<td>1,600,000</td>
<td>408K</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>1,200,000</td>
<td>336K</td>
</tr>
<tr>
<td>Kenya</td>
<td>1,400,000</td>
<td>326K</td>
</tr>
</tbody>
</table>

TOP 10 COUNTRIES supplied with TLD by MPP licensees in 2022

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PACKS SUPPLIED (30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>43 M</td>
</tr>
<tr>
<td>Uganda</td>
<td>20 M</td>
</tr>
<tr>
<td>Tanzania</td>
<td>19 M</td>
</tr>
<tr>
<td>Mozambique</td>
<td>16 M</td>
</tr>
<tr>
<td>Malawi</td>
<td>13 M</td>
</tr>
<tr>
<td>Nigeria</td>
<td>13 M</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>12 M</td>
</tr>
<tr>
<td>Zambia</td>
<td>12 M</td>
</tr>
<tr>
<td>Kenya</td>
<td>12 M</td>
</tr>
<tr>
<td>India</td>
<td>10 M</td>
</tr>
</tbody>
</table>

TOP 10 COUNTRIES supplied with DTG 50mg by MPP licensees in 2022

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PACKS SUPPLIED (30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>8 M</td>
</tr>
<tr>
<td>India</td>
<td>3 M</td>
</tr>
<tr>
<td>Malawi</td>
<td>505K</td>
</tr>
<tr>
<td>Thailand</td>
<td>504K</td>
</tr>
<tr>
<td>Mozambique</td>
<td>502K</td>
</tr>
<tr>
<td>Zambia</td>
<td>445K</td>
</tr>
<tr>
<td>Nigeria</td>
<td>423K</td>
</tr>
<tr>
<td>Tanzania</td>
<td>408K</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>336K</td>
</tr>
<tr>
<td>Kenya</td>
<td>326K</td>
</tr>
</tbody>
</table>
In 2022, DTG 10mg for infants was supplied in 66 countries by MPP licensees, an increase of 38 from the previous year. Dolutegravir, both adult and paediatric, either on its own or in combination has been supplied in 126 countries.

NEW COUNTRIES supplied in 2022 with DTG DT 10mg scored the WHO recommended paediatric treatment for infants

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>CHILDREN LIVING WITH HIV</th>
<th>DTG DT 10 mg (Packs of 30’s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Togo</td>
<td>8,700</td>
<td>108K</td>
</tr>
<tr>
<td>Ghana</td>
<td>27,000</td>
<td>68K</td>
</tr>
<tr>
<td>Guinea</td>
<td>11,000</td>
<td>65K</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>6,000</td>
<td>48K</td>
</tr>
<tr>
<td>Sudan</td>
<td>3,300</td>
<td>44K</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>11,000</td>
<td>43K</td>
</tr>
<tr>
<td>Vietnam</td>
<td>4,900</td>
<td>40K</td>
</tr>
<tr>
<td>Niger</td>
<td>2,700</td>
<td>27K</td>
</tr>
<tr>
<td>Ukraine</td>
<td>2,700</td>
<td>22K</td>
</tr>
<tr>
<td>Somalia</td>
<td>1,000</td>
<td>20K</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>3,700</td>
<td>18K</td>
</tr>
<tr>
<td>Panama</td>
<td>-</td>
<td>14K</td>
</tr>
<tr>
<td>Senegal</td>
<td>4,000</td>
<td>13K</td>
</tr>
<tr>
<td>Madagascar</td>
<td>3,500</td>
<td>4K</td>
</tr>
<tr>
<td>Mauritania</td>
<td>1,000</td>
<td>4K</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>6,100</td>
<td>3K</td>
</tr>
<tr>
<td>Laos</td>
<td>1,000</td>
<td>2K</td>
</tr>
<tr>
<td>Cabo Verde</td>
<td>100</td>
<td>2K</td>
</tr>
<tr>
<td>Moldova</td>
<td>200</td>
<td>2K</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>-</td>
<td>1K</td>
</tr>
<tr>
<td>Djibouti</td>
<td>200</td>
<td>1K</td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>-</td>
<td>1K</td>
</tr>
<tr>
<td>El Salvador</td>
<td>500</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Cuba</td>
<td>200</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>1,000</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Georgia</td>
<td>100</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Jamaica</td>
<td>500</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Paraguay</td>
<td>500</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Yemen</td>
<td>1,000</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Tunisia</td>
<td>200</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Armenia</td>
<td>100</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Bhutan</td>
<td>-</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Sao Tome and Principe</td>
<td>-</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Honduras</td>
<td>1,000</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>500</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Comoros</td>
<td>-</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>Belize</td>
<td>100</td>
<td>&lt;1K</td>
</tr>
<tr>
<td>South Africa</td>
<td>270,000</td>
<td>&lt;1K</td>
</tr>
</tbody>
</table>

TOP 10 COUNTRIES supplied with DTG DT 10mg scored for infants by MPP licensees in 2022

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>CHILDREN LIVING WITH HIV</th>
<th>DTG DT 10 mg (Packs of 30’s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mozambique</td>
<td>150,000</td>
<td>1M</td>
</tr>
<tr>
<td>Uganda</td>
<td>88,000</td>
<td>837K</td>
</tr>
<tr>
<td>Zambia</td>
<td>66,000</td>
<td>726K</td>
</tr>
<tr>
<td>Tanzania</td>
<td>96,000</td>
<td>553K</td>
</tr>
<tr>
<td>Malawi</td>
<td>58,000</td>
<td>488K</td>
</tr>
<tr>
<td>Kenya</td>
<td>83,000</td>
<td>477K</td>
</tr>
<tr>
<td>Nigeria</td>
<td>170,000</td>
<td>212K</td>
</tr>
<tr>
<td>Congo DR</td>
<td>63,000</td>
<td>147K</td>
</tr>
<tr>
<td>Cameroon</td>
<td>33,000</td>
<td>145K</td>
</tr>
<tr>
<td>Congo</td>
<td>12,000</td>
<td>123K</td>
</tr>
</tbody>
</table>
FOCUS ON PARTNERSHIP: GAP-f

MPP’s commitment to shaping the global innovation and access landscape for better paediatric medicines in 2022 was further demonstrated by the role we played in the Global Accelerator for Paediatric Formulations (GAP-f) network.

Appropriate medicines to save and improve the lives of infants and children often do not exist; if they do, they are sometimes unavailable or not quality-assured, especially in low- and middle-income countries. This lack of optimal medicines in appropriate paediatric formulations puts children’s lives at risk.

The vision of GAP-f is therefore that all children should have equitable access to the medicines they need. Children are not small adults, and infants are distinct from children. They cannot swallow tablets or capsules, often cannot bear the taste of liquid medicines and metabolise drugs differently as they develop and grow. We recognise that their medicines need to be palatable, scored, crushable, dispersible, chewable, sprinkled on food or mixed with breast-milk and available where they are needed.

High-quality and affordable access for all children.

GAP-f’s focus is to develop and deliver appropriate, high-quality, affordable and accessible medicines for all children.

Collaboration across stakeholder groups identifies gaps, sets priorities for needs, and accelerates product investigation, development and delivery. This in turn helps to bring universal health coverage one step closer to reality.

MPP’s series of contributions to GAP-f’s new Strategy 2022–2024 allows us to continue to help tackle a broader set of diseases; it will bring us closer to our vision for all children to have equitable access to the medicines that are adapted to their needs.

The rapid rollout of paediatric DTG (pDTG) is a priority for children living with HIV. To ensure this transition to pDTG is undertaken safely and effectively, the GAP-f pDTG Task Team – co-led by MPP – developed a series of considerations for national HIV programmes, implementing partners, and service providers.

High-quality and affordable access for all children.

Collaboration across stakeholder groups identifies gaps, sets priorities for needs, and accelerates product investigation, development and delivery. This in turn helps to bring universal health coverage one step closer to reality.

MPP’s series of contributions to GAP-f’s new Strategy 2022–2024 allows us to continue to help tackle a broader set of diseases; it will bring us closer to our vision for all children to have equitable access to the medicines that are adapted to their needs.

The rapid rollout of paediatric DTG (pDTG) is a priority for children living with HIV. To ensure this transition to pDTG is undertaken safely and effectively, the GAP-f pDTG Task Team – co-led by MPP – developed a series of considerations for national HIV programmes, implementing partners, and service providers.

WHAT OUR PARTNERS SAY

MPP was a founding member of GAP-f. From the very start MPP was able to identify the group’s potential and how it should be built to make it work most effectively. That made a tremendous difference and MPP’s contribution was phenomenal.

MPP really helps us to reflect together on the challenges of adapting models – such as the response to HIV – for new disease areas. MPP also leads the way on assessing the effectiveness of recent developments with long-acting technologies and how these technologies could be applied and become accessible in the future. High-level engagement with civil society and those that work towards greater access to medicines in general cannot be underestimated.

The licensing agreements that are the basis for generic formulations are often taken for granted, but they shouldn’t be – because without those, we wouldn’t be able to develop formulations that are accessible to low- and middle-income countries.

DR. MARTINA PENAZZATO IS THE GAP-f TEAM LEAD IN THE RESEARCH FOR HEALTH, SCIENCE DIVISION AT THE WORLD HEALTH ORGANIZATION
Greater global focus required to eliminate Hepatitis C

During the height of the COVID-19 pandemic many low- and middle-income countries deprioritised viral hepatitis. Despite this, MPP continues to invest time and effort in working with stakeholders to support access and scale-up of HCV treatments as well as exploring opportunities where further licensing or licence expansion can contribute to expanding access.

Despite the tools available, in 2019 there were still three million new HBV and HCV infections combined and more than a million deaths\(^3\).

With some notable exceptions, most countries have fallen behind in their provision of HCV care and treatments. Fortunately, in May 2022 WHO’s 194 member states adopted a new global strategy for viral hepatitis covering the period until 2030. All countries committed to a roadmap for its elimination.

THE KEY POINTS OF THIS ROADMAP ARE:

- A greater promotion of public and political awareness about the importance of hepatitis B and C prevention, testing and treatment
- Health and health systems need to be viewed holistically as health is fundamentally about people and not disease
- Service delivery must be simplified and brought closer to communities. Part of the reason why only 20 per cent of those with hepatitis B or C know they are living with a life-threatening virus is because services, and in particular diagnostics, are not readily accessible

Innovation is still needed, such as long-acting treatments, with the aim that a single injection will be enough for a cure. MPP already holds a licence for a technology that could potentially – if demonstrated to be safe and effective – allow for more affordable versions in even the poorest countries.

Daclatasvir – or DAC for short – is a curative regimen for HCV infection when used in combination with other medications. It became available for low- and middle-income countries after MPP and originator company Bristol Myers Squib signed a licence agreement in 2016, which enabled generic manufacturers to produce and supply the drug.

### Key Facts and Stats for 2022

**For the first time in 2022**

- Belarus
- Guyana
- Paraguay
- Afghanistan
- Chad
- Guinea

were all supplied with DAC and or DAC combinations

---

**TOP 10 COUNTRIES supplied with DAC and or DAC combinations by MPP licensees in 2022**

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PEOPLE LIVING WITH HCV</th>
<th>DAC/DAC (Packs of 28's)</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>6,055,000</td>
<td>32K</td>
</tr>
<tr>
<td>Rwanda</td>
<td>96,700</td>
<td>22K</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>378,000</td>
<td>17K</td>
</tr>
<tr>
<td>Ukraine</td>
<td>1,321,000</td>
<td>13K</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>234,000</td>
<td>11K</td>
</tr>
<tr>
<td>Belarus</td>
<td>278,000</td>
<td>7K</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>640,000</td>
<td>4K</td>
</tr>
<tr>
<td>Cambodia</td>
<td>262,000</td>
<td>3K</td>
</tr>
<tr>
<td>Cuba</td>
<td>55,200</td>
<td>3K</td>
</tr>
<tr>
<td>Malaysia</td>
<td>380,000</td>
<td>2K</td>
</tr>
</tbody>
</table>

---

The prices of MPP-licensed HCV generics were **significantly lower than originator prices** thus making essential, high-quality medicines more affordable for people in low- and middle-income countries.

In 2022 the average treatment cost of DAC using the innovators’ product in low- and middle-income countries was USD 952 but the **average cost** of the generic product stood at USD 53.

This means there was an average price reduction of **94%** for DAC products sold by MPP licensees.

By the end of 2022 DAC had been commercialised in 37 countries by MPP licensees.

By the end of 2022 **+1.4M DAC or DAC combination treatments had been made available through MPP licence.**

---

HCV TREATMENT: KEY FACTS AND STATS FOR 2022
Novel medical technologies

MPP’s exciting move into a new area with the potential for life-changing medicines

MPP’s licensing model originally focused only on small molecules in oral formulations. Now, with more complex technologies emerging that could lead to significant improvements in public health, we have been developing ways to support efforts to make these long-acting technologies, biotherapeutics and mRNA vaccines available and affordable in low- and middle-income countries.

CAB-LA to expand HIV prevention options for the most vulnerable

In July, MPP signed a voluntary licensing agreement with Viiv Healthcare for cabotegravir (CAB) long-acting (LA) for HIV Pre-Exposure Prophylaxis (PrEP). Subject to regulatory approvals, this bold move gives the go-ahead for manufacturers in at least 90 low- and middle-income countries to develop and supply CAB-LA to prevent HIV infection.

The negotiation of the licence is an excellent example of MPP’s continued commitment to making innovation available and affordable in low- and middle-income countries.

The agreement also came just seven months after the first regulatory approval of CAB-LA for HIV PrEP anywhere in the world, by the USFDA.

Although oral PrEP options are available in many countries, challenges with adherence and stigma have meant that these options have not had the impact they could have had. Long-acting technologies, on the other hand, open up a new dimension that could lead to greater uptake. By providing a much-needed additional option for those at risk, access to this prevention measure could significantly contribute towards the goal of ending the HIV epidemic.

WHAT OUR PARTNERS SAY

AfroCAB Treatment Access Partnership and our many community partners welcome this announcement regarding the generic licensing of CAB-LA. CAB-LA will undoubtedly have a transformative impact on HIV prevention efforts in our communities. We are pleased to see that Affordable and community partners’ advocacy around CAB-LA access did not go unheard. We now eagerly and anxiously await a bridging price to make CAB-LA accessible in low- and middle-income countries. Now, we look forward to working with all stakeholders to ensure that the promise of CAB-LA is realised.

Jacque Wambui is an HIV-positive activist currently serving on the AfroCAB Treatment Access Partnership Community Advisory Board.

We’re delighted with the progress that we’ve made through the licences with MPP. Enabling access to antiretrovirals is core to our ambition to see the end of HIV as a public health threat. We can’t do that on our own, and it is critical for us to work through partnerships. Our partnership with MPP represents the single biggest partnership we have that is really used to accelerate and drive access to our innovative medicines all over the globe.

Helen McDowell is the Head of Government Affairs and Global Public Health for Viiv Healthcare.

MPP’s exciting move into a new area with the potential for life-changing medicines

MPP’s licensing model originally focused only on small molecules in oral formulations. Now, with more complex technologies emerging that could lead to significant improvements in public health, we have been developing ways to support efforts to make these long-acting technologies, biotherapeutics and mRNA vaccines available and affordable in low- and middle-income countries.

We’re delighted with the progress that we’ve made through the licences with MPP. Enabling access to antiretrovirals is core to our ambition to see the end of HIV as a public health threat. We can’t do that on our own, and it is critical for us to work through partnerships. Our partnership with MPP represents the single biggest partnership we have that is really used to accelerate and drive access to our innovative medicines all over the globe.

Helen McDowell is the Head of Government Affairs and Global Public Health for Viiv Healthcare.
FOCUS ON PARTNERSHIP: THE COALITION TO ACCELERATE ACCESS TO LONG-ACTING PRE-EXPOSURE PROPHYLAXIS

The Coalition to Accelerate Access to Long-Acting Pre-Exposure Prophylaxis (LA PrEP Coalition) is an initiative that brings together leading donors, agencies and advocates to further help combat HIV. Its purpose is simply to make longer-acting PrEP options accessible as quickly and as equitably as possible.

The Coalition is convened by Unitaid, WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and the Global Fund, with AVAC as the secretariat. MPP’s key contribution is through the licensing of novel long-acting PrEP products and technologies to enable the development and supply of generic versions in low-and middle-income countries. The Coalition’s initial focus is on CAB-LA as a platform for next-generation options.

Long-acting technology licence to help tackle scourge of malaria

September saw the signing of an MPP voluntary licence agreement for mdc-STM with French pharmaceutical company MedinCell. This long-acting injectable formulation may help tackle the transmission of malaria, which tragically remains endemic in 91 countries, home to 50 per cent of the world’s population. According to WHO estimates, 247 million people were infected worldwide with malaria in 2021,95 per cent of them in Africa; this led to 627,000 deaths. Children under five are the most vulnerable, accounting for 80 per cent of deaths from the disease.

Manufacturing can take place in any country worldwide for distribution in low- and middle-income countries.

The product is based on BEPO®, a MedinCell technology that enables the sustained release of ivermectin after a single injection. It is administered subcutaneously at the beginning of the malaria-transmission season to people living in malaria-endemic areas. Mosquitoes feeding on people who have received the ivermectin injection will be killed and thus prevent further malaria transmission.

If proven efficacious this may bring enormous benefits to the whole community by reducing the risk of transmission, especially in children.

WHAT OUR PARTNERS SAY

MITCHELL WARREN is the Executive Director of AVAC

A huge proportion of the world’s population are afflicted by the diseases we are working on at CELT. Long-acting medicines hold the promise to be transform treatment and prevention of infectious diseases.

Too often, there is insufficient consideration of low- and middle-income needs and the collaboration with MPP ensures that this is considered upfront in our development programmes. MPP’s role means that we are able to address these factors which are so important to us, while being able to concentrate on what we are good at, safe in the knowledge that other elements are being addressed.

ANDREW OWEN is a Professor of Pharmacology and the Director of the Centre of Excellence in Long-Acting Therapeutics (CELT) at the University of Liverpool

September saw the signing of an MPP voluntary licence agreement for mdc-STM with French pharmaceutical company MedinCell. This long-acting injectable formulation may help tackle the transmission of malaria, which tragically remains endemic in 91 countries, home to 50 per cent of the world’s population. According to WHO estimates, 247 million people were infected worldwide with malaria in 2021,95 per cent of them in Africa; this led to 627,000 deaths. Children under five are the most vulnerable, accounting for 80 per cent of deaths from the disease.

Following this agreement, MPP can now identify suitable generic manufacturing companies to develop and commercialise this injectable version of ivermectin.
THE FOLLOWING IS A SUMMARY OF MPP’S ACTIVITIES IN THE LONG-ACTING FIELD:

3 licences for investigational long-acting technologies and their applications in the field of HIV, TB and Malaria

1 licence for an approved long-acting injectable to prevent HIV (CAB-LA)

1 dedicated website LAPal for a selection of long-acting therapeutics patents and licences

In May-June 2022 a series of roundtables meetings took place about long-acting, in the context of the Industry Liaison Forum led by IAS. MPP co-hosted the third roundtable.

Biotherapeutics such as recombinant proteins and monoclonal antibodies (mAbs) have become mainstays in the treatment of many diseases. The proportion of biotherapeutics among new drug approvals has significantly increased in recent years, as has the number of biotherapeutics included in WHO’s Essential Medicines List. However, a combination of health system challenges, higher prices and barriers to market entry have hindered broad access to biotherapeutics. This is especially the case in low- and middle-income countries. For example, just one per cent of mAbs are currently being supplied in Africa.

MPP is now working to develop a model to facilitate equitable access to biotherapeutics in low- and middle-income countries through licensing and technology transfer.

**Significant MPP article published in ‘The Lancet Global Health’**

In 2022, MPP published an important paper in a leading public health journal, Lancet Global Health. Following a request by WHO’s Essential Medicines Expert Committee, we investigated how licensing could improve both affordability and timely access to biotherapeutics in low- and middle-income countries. It was the findings of this investigation that were published by The Lancet Global Health.

This research saw MPP leveraging expert consultations, literature and data analysis, and internal technical knowledge. As a result, various salient elements were identified to encourage greater access to affordable biosimilars in low- and middle-income countries:

- Prioritising potential biotherapeutic targets according to their potential for public health impact
- Supporting biosimilar product and clinical development, including through technology transfer to expedite regulatory approval
- Facilitating biosimilars’ entry and use in low-and middle-income countries by meeting procurement, supply chain and health system requirements

**FOCUS ON PARTNERSHIP**

The Access to Medicine Foundation’s research has found that MPP has been the gold standard on voluntary licensing arrangements between originator pharmaceutical companies and generic medicine manufacturers, enabling broad access to people worldwide with a range of treatments. I believe more opportunities exist to use this model for the years to come, saving more lives. We incentivise companies to expand access using methods such as voluntary licensing, and without the MPP, the scale and scope of access will be limited to benefit only a few patients worldwide.

**JAYASREE K. IYER IS CEO OF THE ACCESS TO MEDICINE FOUNDATION**

We are very much philosophically aligned with MPP in terms of the goals of creating important lifesaving innovations to be available to all people who need them. Monoclonal antibody technology is one area that IAVI has recently been very active in terms of research and development.

MPP serves a very important role in access to innovative health products and its track record has been very positive. The licensing mechanism is very important. I think that makes MPP a partner who can be trusted by different sectors and who may have previously looked at these kind of initiatives around access and IP licensing with some scepticism. There’s really no other organisation that has the specific focus that MPP does. MPP is an important partner because it’s very clear that no one organisation can solve these challenges by itself. The global health ecosystem would be significantly worse off if MPP did not exist.

**DR. MARK FEINBERG IS PRESIDENT AND CEO OF THE INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI)**

Gates MRI is member of the Project to Accelerate New Treatments for Tuberculosis collaboration. The collaboration aims to identify novel regimens that could treat both drug-susceptible and drug-resistant forms of TB in a much shorter duration than the currently used treatment regimens.

A key drug in the proposed regimen is sutezolid, a promising antibiotic drug candidate. In combination with other drugs, it could potentially be used as an all-oral, shortened regimen for all forms of TB, including DR-TB. In December 2020, MPP and Gates MRI signed an agreement to advance the development of this investigational drug for use in low- and middle-income countries.

We very much welcome MPP’s work to facilitate the development of medicines for low- and middle-income countries and enables access to such medicines. This licensing of medicines and vaccines serves the underserved, a critically important role. We look forward to MPP continuing to be an integrator and collaborator – as well as a negotiator and problem-solver – by establishing further opportunities to facilitate market access for life-saving medicines.

**DR. CHARLES WELLS IS THE HEAD OF THERAPEUTICS DEVELOPMENT AT THE BILL AND MELINDA GATES RESEARCH INSTITUTE**
Non-communicable diseases

MPP SIGNS FIRST-EVER CANCER LICENCE FOR LOW- AND MIDDLE-INCOME COUNTRIES

Recent years have seen tremendous progress with new technologies to treat cancer. Major challenges persist in low- and middle-income countries, however.

These countries still face great difficulties accessing new-generation cancer medicines – readily available to wealthier nations – that would allow patients to enjoy a better quality of life and to live longer.

**Nilotinib is the first cancer licence with a public health focus anywhere in the world.**

We are delighted that 2022 saw MPP sign the first ever voluntary licence agreement with Novartis to combat cancer in low- and middle-income countries.

Nilotinib, a twice-daily oral medication used to treat chronic myeloid leukaemia in adults and children at least one year old, will now become available to thousands of patients in low- and middle-income countries. The agreement with originator company Novartis AG means that generic companies will be able to produce and supply the medicine at affordable cost.

The licence in particular includes seven middle-income countries for which longer secondary patents on the product are pending or in force: Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia.

**PRECEDENT FOR OTHER COMPANIES TO FOLLOW**

Access to high-quality medicines is a crucial component of the global health response to cancer.

This first-ever voluntary licence for a non-communicable disease sets a precedent which it is hoped will be followed by other originator pharmaceutical companies.

**FOCUS ON PARTNERSHIP: THE ACCESS TO ONCOLOGY MEDICINES COALITION**

In May 2022, MPP joined the Access to Oncology Medicines (ATOM) Coalition. Led by the Union for International Cancer Control, the aim of this new global initiative is twofold: to improve access to essential cancer medicines in low- and lower-middle-income countries, and to increase the capacity for diagnosing cancer and for the proper handling and supply monitoring of these medicines.

MPP’s role in the Coalition is to facilitate affordable access to cancer treatments through non-exclusive licences to generic manufacturers.

The approach that the ATOM Coalition has taken for the acquisition of new medications for cancer patients in low- and lower-middle-income countries includes on-patent and off-patent medications. Sustained financially accessible on-patent medicines are only possible through voluntary licences (VLs). MPP’s depth and breadth of experience and knowledge in utilizing VLs for infectious diseases makes them the ideal partner for the ATOM Coalition to tackle the complexity and diversity of cancer therapies. Without a full spectrum of medications that MPP’s participation and contribution will create, we would fail to meet the needs of our patients.

**WHAT OUR PARTNERS SAY**

**DR. DAN MILNER IS ATOM’S EXECUTIVE DIRECTOR**

Other than explaining the scientific evidence of disease, our first contact with the patient is too often having to explain the issue of cost. Not everybody can afford to be treated especially if the treatment is to last months and months. Pakistan along with other low-middle-income countries has a weak national health infrastructure for the treatment of cancer. Significant health inequities exist in LMICs, the government usually provides basic chemotherapies unfortunately expensive targeted therapies are not provided by the government.

I am very excited about the successful negotiation for nilotinib by MPP. With greater availability of cheap but high-quality drugs, more patients will have access to treatment without significant financial toxicities. From my point of view, even though CML is an uncommon disease but access to Nilotinib will make a major difference. I’m very hopeful that once this one cancer drug becomes available through generic manufacturers, then it will encourage the manufacturing and availability of other cancer drugs too. I believe every drop in the ocean counts. Thus, significant savings with high-quality generics will help the governments to divert the savings for prevention early diagnosis, and treatment for other cancers.

MPP is doing a fantastic job of negotiating licences and getting things done. I’m very hopeful that MPP’s role in negotiating with other drug companies will help in licences for generic drugs for other diseases which are major public health problems (lung, breast, colon). MPP will further expand access to generic drugs in low and middle-income countries and provide us with more affordable medicines. MPP has been of invaluable help, and I hope they continue to provide help for our part of the world. Congratulations MPP.

**DR. ZEBA AZIZ IS A MEDICAL ONCOLOGIST WORKING IN PAKISTAN**
COVID-19

NEW LICENCE AGREEMENTS DEMONSTRATE MPP’S READINESS FOR FUTURE PANDEMICS

The world’s response to COVID-19 highlighted the shocking inequities that still exist in global health today. But that same response also drew attention to a range of mechanisms that could improve affordable access to health products in low- and middle-income countries. Pandemic preparedness and response (PPR) must above all avoid a repeat of past failures and prevent the devastation wreaked by COVID-19.

MPP HELPS WORLD PREPARE FOR NEXT PANDEMIC

Preparations for future pandemics are now underway, with new mechanisms being established. Discussions revolve around how best to streamline and accelerate access to diagnostics tools, vaccines and treatments for those living in low- and middle-income countries.

Preparation is coalescing around the following instruments:

- The newly created and WHO-led Intergovernmental Negotiating Body (INB) is negotiating a legally binding international ‘pandemic accord’
- International Health Regulations are an existing PPR tool currently under review
- A review of WHO’s Health Emergency preparedness and response architecture aims to address gaps in health emergency governance, systems and financing mechanisms
- The Pandemic Fund is managed by the World Bank and WHO. US$1.6 billion has been raised since its inception in mid-2022, but there is still an estimated annual PPR funding gap of $10 billion
- The 100 Days Mission is an agenda to develop diagnostics, therapeutics and vaccines within the first 100 days of a pandemic threat being detected

FOCUS ON PARTNERSHIP

We support the WHO’s work in promoting efforts to enhance pandemic PPR governance, systems, and financing in accordance with member states. We recognize the role innovative and flexible partnerships in global health, such as Gavi, the Global Fund, CEPI, Unitaid, FIND, and the Medicines Patent Pool, can play in close collaboration with WHO, UNICEF and its Member States in building global health resilience and response capacity against future pandemic threats.

EXTRACT FROM G20 PRESIDENCY CHAIR’S SUMMARY
THE SECOND G20 JOINT FINANCE AND HEALTH MINISTERS’ MEETING
Bali, Indonesia, 12 November 2022

MPP’s urgent response to COVID-19 was invaluable experience for any future pandemic

- Advocated to try to ensure that all salient policies and initiatives incorporated licensing and technology transfer as mechanisms for achieving equitable access to medical countermeasures
- Made significant contributions to G7 and G20 processes for pandemic preparedness and response
- Undertook advocacy with governments and funding bodies
- Contributed to discussions at the INB meetings and other forums
- Initiated engagement with organisations developing antivirals against pathogens with pandemic potential
- Positioned the mRNA Technology Transfer Programme as vital tool for PPR
ACT-A’s 2022 report recommended that: “To further strengthen pandemic preparedness it is important for WTO (World Trade Organization), WHO and Medicines Patent Pool (MPP) to build and strengthen strategies for generic licensing and technology transfer for therapeutics, including relevant TRIPS procedures, with input from industry partners and stakeholders. The aim of this is to accelerate access of novel products for all low- and middle-income countries and increase diversified manufacturing.”


Contributions to the Access to Covid Tools Accelerator (ACT-A) framework formed a key plank of MPP’s support for international pandemic response in 2022. ACT-A is a global collaboration that contributed to the development, production and access to COVID-19 tests, treatments and vaccines.

27 generic manufacturers to supply 105 countries with oral COVID-19 treatment.

This news came on the heels of a series of notable MPP successes to combat COVID-19 in 2022.

First, in January, we signed agreements with 27 generic manufacturing companies to produce the oral COVID-19 antiviral molnupiravir for supply in 105 low- and middle-income countries. These sublicence agreements were the result of the voluntary licensing agreement signed the previous October by MPP and MSD, a trade name of Merck & Co.

As with all our non-exclusive sublicences, the agreement allows generic manufacturers to produce both the raw ingredients for molnupiravir or the finished drug itself. The companies offered the sublicence were obliged to meet MPP’s requirements for regulatory compliance, as well as international standards for quality-assured medicines. The companies span 11 countries: Bangladesh, China, Egypt, India, Indonesia, Jordan, Kenya, Pakistan, South Africa, South Korea and Vietnam.

MPP EXPANDS REACH BY SIGNING FIRST EVER LICENCE WITH JAPANESE COMPANY

Throughout 2022, MPP remained steadfast in its commitment to the development and production of COVID-19 treatment by generic manufacturers in low- and middle-income countries. October saw us sign a licensing agreement with Shionogi, one of Japan’s leading pharmaceutical companies, for their antiviral candidate ensitrelvir fumaric acid (S-217622). Following regulatory approval, Ensitrelvir will act as a COVID-19 treatment to be administered as an oral tablet taken once daily for five days.

Pending regulatory approval, MPP is now authorised to grant sublicences to manufacturers to develop generic versions of the product and supply ensitrelvir in 117 countries.

This means that many more people from low- and middle-income countries will have access to COVID-19 treatment.
27 sublicences signed with MPP for molnupiravir

- Bangladesh: Beximco Pharma, Incepta
- China: Bright Gene, Desano, Fosun Pharma, Langhua, Lonza
- India: Arene Lifescience, Biophore, BDR, Laurus Labs, Lupin
- Indonesia: Kimia Farma
- South Africa: Aspen, CPT Pharma
- Pakistan: Remington
- Singapore: GlaxoSmithKline
- South Korea: Celltrion, Dongyang FTL, Hanmi Pharm
- Vietnam: Stella
- Bangladesh (Raw ingredients): Beximco Pharma, Incepta
- China (Raw ingredients): Bright Gene, Desano, Fosun Pharma, Langhua, Lonza
- India (Raw ingredients): Arene Lifescience, Biophore, BDR, Laurus Labs, Lupin
- Indonesia (Raw ingredients): Kimia Farma
- South Africa (Finished drugs): Aspen, CPT Pharma
- Pakistan (Finished drugs): Remington
- South Korea (Finished drugs): Celltrion, Dongyang FTL, Hanmi Pharm
- Vietnam (Finished drugs): Stella

- Raw ingredients
- Finished drugs
- Raw ingredients and finished drugs
A FURTHER 38 GENERIC MANUFACTURERS TO HELP SUPPLY COVID-19 TREATMENT TO 53% OF WORLD POPULATION

Then in March, MPP signed agreements with 35 companies to manufacture the generic version of Pfizer's oral COVID-19 treatment nirmatrelvir. In combination with a low dose of ritonavir, this can be supplied in 95 low- and middle-income countries and was the result of a voluntary licensing agreement between MPP and Pfizer in November 2021. Overall, this will help enable the supply of these vital medicines to 53 per cent of the world’s population.

Six companies will focus on producing the drug substance, nine will develop the product itself and the remainder will do both. The companies cover 12 countries: Bangladesh, Brazil, China, Dominican Republic, Jordan, India, Israel, Mexico, Pakistan, Serbia, Republic of Korea and Vietnam.

Darnitsa, a Ukrainian company, was unable to sign the initial agreement because of the sudden onset of the war with Russia. Later in the month, however, MPP was delighted to announce that the company had also become one of the sublicensees. This therefore brought the number of signatory companies to 36, and the total number of countries to 13.

And by July, the total number had risen to 38 companies across the world.

38 sublicences signed with MPP for nirmatrelvir (update July 2022)

Record approval time for MPP-enabled generic formulation

subsequent approval under the MPP nirmatrelvir licence, but the approval took place in record time.

Of the 18 COVID-19 products filed by generic companies in 2022, Hetero’s nirmatrelvir/ritonavir was approved on 25 December 2022 by WHO-PQ.

Just 300 days elapsed between MPP’s signing the sub-licence agreement with Hetero and final approval, and a mere 165 days between filing and approval. On average, it takes between 18 to 24 months for a product to be approved by the WHO-PQ or a Stringent Regulatory Authority after filing.
MPP AND COVID-19: KEY FACTS AND STATS FOR 2022

The success of the COVID-19 licence agreements secured in 2021 meant that MPP signed an unprecedented number of sublicense agreements in 2022.

- The geographical spread of MPP's sub-licensees has expanded from six to 16 countries, demonstrating that manufacturers on every continent are able to meet MPP's stringent and highest-quality requirements and thus contribute to health security.
- Two agreements were signed with the United States National Institutes of Health (NIH) for 11 innovative therapeutics, early-stage vaccines and diagnostic tools.
- One agreement was signed with Shionogi for ensitrelvir fumaric acid, an oral antiviral.
- By the end of the year, 27 and 38 generic manufacturers respectively had signed sub-licence agreements with MPP to develop products under the molnupiravir and nirmatrelvir licences.
- Out of these 59 sub-licensees, 38 are companies which MPP has never worked with before.
- By the end of 2022, 52 COVID-19 products were under development as a result of the therapeutics' licences secured in 2021.
- Of these 52 products, 18 were filed last year with WHO-PQ or the US Food and Drug Administration (USFDA), with 34 to follow.
- Of the 18 filed in 2022, Hetero’s nirmatrelvir/ritonavir was approved in December 2022 by WHO-PQ.
- With an average approval time by a Stringent Regulatory Authority of anywhere between 18-24 months, this particular approval took place in record time, just 165 days or five-and-a-half months.
- Exceptionally, in 2022 four molnupiravir licensees supplied 548,051 treatments’ courses in India and Guatemala.

What we at Hetero find most useful is the support we receive from MPP’s Indian office, this can be on the industry landscape reports with the market share and regulatory approvals of licensed products or providing clarity on the patent situation in different markets. This sharing of scientific and commercial updates gives us a better understanding of the market and our positioning. The MPP team also helps resolve technical issues which may arise in product development and filing with regulatory authorities. What appeals to us in MPP licences is that it ensures a level playing field for all the sublicensees with the terms and conditions, territory, and timelines common to all.

What our partners say

WHAT OUR PARTNERS SAY

What we at Hetero find most useful is the support we receive from MPP’s Indian office, this can be on the industry landscape reports with the market share and regulatory approvals of licensed products or providing clarity on the patent situation in different markets. This sharing of scientific and commercial updates gives us a better understanding of the market and our positioning. The MPP team also helps resolve technical issues which may arise in product development and filing with regulatory authorities. What appeals to us in MPP licences is that it ensures a level playing field for all the sublicensees with the terms and conditions, territory, and timelines common to all.

BHAVESH SHAH IS THE DIRECTOR OF INTERNATIONAL MARKETING FOR HETERO, A GENERIC PHARMACEUTICAL COMPANY BASED IN INDIA.
mRNA Technology Transfer Programme

MPP HELPS TO ENSURE LONG-TERM REGIONAL HEALTH SECURITY

The COVID-19 pandemic underscored the gross inequity that exists with global access to health products, especially vaccines. The ubiquity and costs of the COVID-19 pandemic have finally focused attention on equitable access and created an opportunity to invest in long-term regional health security.

The mRNA Technology Transfer Programme

Was set up to address the inequalities in access to vaccines in low- and middle-income countries that emerged during the COVID-19 pandemic.

The objectives of the Programme are to establish and enhance sustainable mRNA vaccine manufacturing capacity and to develop skilled human capital in the regions where mRNA vaccine manufacturing capacity is limited or non-existent. The programme is based around a technology transfer “hub” Afrigen, which is located in South Africa.
Afrigen drew up and distributed a laboratory manual for the preparation of the mRNA COVID-19 vaccine at laboratory small scale. This includes a description of the plasmid design, the manufacturing process – starting from plasmid linearisation and up to lipid nanoparticle formulation – the laboratory layout, the list of necessary equipment and raw materials, as well as the description of analytical methods deployed for drug substance and drug product characterisation. The manual has been distributed to all partners signing a technology transfer agreement, as well as those receiving the introductory training.

In January 2022, MPP’s partner, the South African Medical Research Council (SAMRC), established the South African mRNA Vaccine Consortium (SAMVAC). This included various institutions responsible for the development of a second-generation improved mRNA technology platform – which would reduce the cost of goods, improve thermostability, increase yields and freedom to operate – and a vaccine pipeline salient for Africa novel mRNA vaccine candidates for SARS-CoV2 and other diseases for low- and middle-income countries.

The SAMRC has also now successfully concluded nine funding agreements with several institutions and transferred funds for Year 1 of the programme to begin; in January 2022 a research commercialisation agreement was also executed between all SAMVAC members.

There have been several stand-out achievements towards the optimisation of the technology and the early development of new vaccine candidates:

- New lipids have been synthesised and successfully tested for their ability to form lipid nanoparticles with the desired characteristics
- New constructs with SARS CoV-2 Omicron variants have been generated and tested in proof-of-concept immunogenicity studies
- Both a TB and HIV project have been initiated (antigen discovery and vaccine development)

The mRNA Technology Transfer Programme has received exceptional support from high-income countries and South African organisations. At the end of 2022, $US 122 million had been confirmed and USD 112 million had already been received to fund activities linked to the South African consortium (71 per cent) and Programme Partners (27 per cent). Funds have been raised both to fully cover SAMVAC’s expenditure for the technology platform development and to partially cover expenditure linked to initial preparatory activities at Programme Partner sites. These preparatory activities include the procurement of critical equipment for mRNA vaccine manufacturing, site assessments, the development and strengthening of local regulatory capabilities, and bio-manufacturing training.

In October, the mRNA Scientific Advisory Committee (mSAC) was established to provide technical support for the programme. Meeting twice a year, this independent group, which draws on a wealth of expertise from the public and private sectors of all continents, will advise MPP and the mRNA Programme Partners about any scientific matters that may arise and reports to MPP’s Executive Director.

The mSAC currently consists of eight members. Experts bring experience from WHO, the Perelman School of Medicine, the University of Pennsylvania, Chulalongkorn University Vaccine Research Center, the National Institute of Allergy and Infectious Diseases Vaccine Research Center, Sanofi Pasteur, Wellcome Leap and Moderna.
FOCUS ON PARTNERSHIP: LATIN AMERICAN MANUFACTURERS COMPLETE FIRST TRAINING AT mRNA TECHNOLOGY TRANSFER PROGRAMME

In March 2022, scientists from two vaccine manufacturing companies from Argentina and Brazil were the first to receive technology transfer training at Afrigen. A group of scientists from Argentina’s Sinergium Biotech and Brazil’s Bio-Manguinhos/Fiocruz travelled to the Hub at Afrigen, Cape Town.

In a three-day course, they learned about Afrigen’s lab-scale mRNA manufacturing process, including formulation of lipid nanoparticles and data analytics, as well as the production and control of vaccines using mRNA technology.

The benefit of this programme is enormous. This programme enables countries to develop and produce mRNA vaccines in their own countries and cover the supply of vaccines where they are needed the most. A lot of big pharmaceuticals refuse to do a tech transfer, specifically of this technology. We saw with COVID-19 that not all countries have equal access to vaccines.

SOTIRIS MISSAILIDIS RESEARCH AND DEVELOPMENT DIRECTOR AT BIO-MANGUINHOS/FIOCRUZ, A RIO DE JANEIRO PUBLIC HEALTH INSTITUTION THAT MANUFACTURES VACCINES FOR YELLOW FEVER AND MENINGOCOCCAL DISEASE FOR BRAZIL AND OTHER LATIN AMERICAN COUNTRIES

The mRNA technology transferred from the Programme will allow companies to manufacture vaccines not only against COVID-19, but against other diseases, including flu and respiratory viruses. There is a huge field to explore in mRNA technology.

SANchez ALBERTI A PROJECT MANAGER AT SINERGIum, A PRIVATE SECTOR BIOPHARMACEUTICAL COMPANY OUTSIDE BUENOS AIRES WHICH MANUFACTURES VACCINES FOR ARGENTINA AND THE REGION

Other companies that have been selected as partners include Biovac from South Africa, African manufacturers from Egypt, Kenya, Nigeria, Senegal and Tunisia, and manufacturers from Bangladesh, India, Indonesia, Pakistan, Serbia, Ukraine and Vietnam.

“The WHO mRNA Technology Transfer Programme is a great opportunity for IPD because it is clearly aligned with our “raison d’être” of accelerating equitable and sustainable access to health. For 80 years, IPD has been manufacturing yellow fever vaccines that meet WHO standards for vaccine quality. We are now ready to leverage this experience and take the next step in our journey by expanding our portfolio. As a partner with the vision to “manufacture vaccines for equity” the mRNA technology represents a great opportunity for at least four reasons:

- Connecting surveillance and manufacturing to accelerate the process between detection of new pathogens and response with an appropriate vaccine
- mRNA technology-based Research and Development: We are in discussions with partners to address Africa’s need for vaccines. Our objective is to build internal capacity and to help develop a portfolio relevant in the long term
- Human capital development: IPD has already significantly strengthened its team by recruiting brilliant young scientists whose extensive backgrounds in infectious disease are already being leveraged to undertake disease surveillance and research
- Technology transfer: An amazing value-add of the hub programme is the sharing of knowledge and know-how that will take place amongst partners

DR AMADOU ALPHA SALL IS THE GENERAL ADMINISTRATOR INSTITUTE PASTEUR DE DAKAR (IPD), SENEGAL
Events and activities

**FEBRUARY 2022**
Dr Tedros Adhanom Ghebreyesus and Minister Meryrame Kitir of Belgium visit Afrigen to underscore the potential to produce vaccines for a wide range of diseases.

**MAY 2022**
Tiwa Braimoh speaks at the Interest conference on facilitating access to COVID-19 antivirals and new long-acting HIV agents in Africa.

**APRIL 2022**
AFRAVIH – MPP’s Head of Business Development, Sandra Nobre is on a panel talking about local production.

**AUGUST 2022**
Launch of ATOM, a new global coalition to increase access to and the use of essential cancer medicines in low and lower middle-income countries.

**JUNE 2022**
Board retreat to Evian to work on MPP’s Strategy 2023-2025.

**JULY 2022**
Unitaid and MPP joint visit with funders from Germany, Canada, Norway and France. Here visiting Aurum Institute in Johannesburg.

To mark the partnership between scientists at Afrigen and the National Institute of Allergy and Infectious Diseases (NIAID), partners of the mRNA Technology Transfer Programme are hosting the first scientific colloquium that MPP helped organise.

The MPP team attends IAS 2022 in Montreal.

3D film making with PVA in South Africa and Senegal. The film was launched at UNGA in New York and used at numerous events to explain the work of the mRNA Technology Transfer Programme.

Charles Gore and Esteban Burrone attend the G20 3rd Health Working Group in Indonesia.

**JUNE 2022**
Launch of ATOM, a new global coalition to increase access to and the use of essential cancer medicines in low and lower middle-income countries.

**JULY 2022**
Meeting during UNGA New York – Ensuring justice, equity and human rights in responses to global health threats – A discussion on the WHO mRNA Technology Transfer Programme included: Adam Taylor, Washington Post; Charles Gore, MPP; Loyce Pace, US Government; Hon Minister Joe Phaahla MOH, South Africa; Winnie Byanyima, ED UNAIDS; Petro Terblanche, CEO Afrigen; Peter Maydarbuk, Public Citizen.
At the Buyer Seller Forum in Cape Town, South Africa, the MPP team carries out interviews with partners and staff on the supply of HIV treatment in LMICs and for World AIDS Day. MPP records messages from its generic manufacturing partners supplying HIV medicines all around the world, including in LMICs.

MPP manages a booth at the World Science Forum in Cape Town on the work of the mRNA Technology Transfer Programme. The programme took part in numerous events. Over 200 people came to see the virtual reality films and President Cyril Ramaphosa also came by.

At the Desmond Tutu Health Foundation in Masiphumelele, South Africa, the MPP team carries out interviews for World AIDS Day with clinical trial participants and health workers from the adolescent clinic.

MPP’s licence agreement signed with the National Institutes of Health under the auspices of the World Health Organisation’s COVID-19 technology access pool (CTAP) for several COVID-19 technologies is selected as a “Deal of Distinction” award winner by the Licensing Executives Society.

MPP helps host a dinner at Afrigen where Dr Jerome Kim, Director General of the International Vaccine Institute (IVI) spoke on mRNA vaccines.

Mila Maistat presents MPP work at EECA Interact, Latvia.

Charles Gore speaks at USP Global Health vaccine manufacturer workshop in Cape Town.

Sébastien Morin attends the High-Level dialogue on paediatric treatment in Rome.

OCTOBER 2022

MPP’s Expert Advisory Group meets in person in Geneva to look over upcoming projects.

Marie-Paule Kieny moderates an important session of the mRNA Technology Transfer Programme at the World Health Summit in Berlin.

For the announcement of the nilotinib licences Charles Gore hosts event in MPP offices.

Giulia Segafredo talks to participants on the MPP work in Cancer at the World Cancer Congress, Geneva.

Esteban Burrone talks on affordability and availability of cancer treatments.

MPP team meets with the Global Health 50/50 team at the World Health Summit in Berlin.

DECEMBER 2022

At the Desmond Tutu Health Foundation in Masiphumelele, South Africa, the MPP team carries out interviews for World AIDS Day with clinical trial participants and health workers from the adolescent clinic.

MPP helps host a dinner at Afrigen where Dr Jerome Kim, Director General of the International Vaccine Institute (IVI) spoke on mRNA vaccines.

Mila Maistat presents MPP work at EECA Interact, Latvia.

Charles Gore speaks at USP Global Health vaccine manufacturer workshop in Cape Town.

Sébastien Morin attends the High-Level dialogue on paediatric treatment in Rome.

MPP manages a booth at the World Science Forum in Cape Town on the work of the mRNA Technology Transfer Programme. The programme took part in numerous events. Over 200 people came to see the virtual reality films and President Cyril Ramaphosa also came by.

Marie-Paule Kieny moderates an important session of the mRNA Technology Transfer Programme at the World Health Summit in Berlin.

For the announcement of the nilotinib licences Charles Gore hosts event in MPP offices.

Giulia Segafredo talks to participants on the MPP work in Cancer at the World Cancer Congress, Geneva.

Esteban Burrone talks on affordability and availability of cancer treatments.

MPP team meets with the Global Health 50/50 team at the World Health Summit in Berlin.

At the Buyer Seller Forum in Cape Town, South Africa, the MPP team carries out interviews with partners and staff on the supply of HIV treatment in LMICs and for World AIDS Day. MPP records messages from its generic manufacturing partners supplying HIV medicines all around the world, including in LMICs.
Focus on partnership

PARTNERSHIP LIES AT THE HEART OF MPP’S WORK.

We could not be as effective and successful without the support, dedication and expertise of other organisations.

MPP’s new partnerships in 2022:

CONSORTIUMS

The LA PrEP Coalition is convened by Unitaid, WHO, UNAIDS, and the Global Fund, with AVAC serving as the Secretariat. This coalition was essential for MPP to secure the CAB-LA for PrEP licensing agreement.

The Global Diabetes Compact Forum is the forum of civil society built as a pillar of the WHO Global Diabetes Compact.

PATENT OFFICES

Overall, MPP sent 32 requests to national patent offices with detailed patents or patent applications to be updated, all with the support of the World Intellectual Property Organization.

CIVIL SOCIETY

Engagement with African Community Advisory Boards, AIDS Vaccine Advocacy Coalition, AWCPAB and several other organisations took place as part of establishing the LA PrEP Coalition. This included playing a key role in various AfroCAB- and AVAC-led community advisory board meetings.

Equally importantly, MPP also participated in two ITPC-led regional community advisory boards: in Latin America and the Caribbean (LATCA CAB, in person) and Middle East and North Africa (MENA CAB, virtually).

ACADEMIA

MPP’s relationship with academia was also strengthened over the course of 2022 with the publication of several peer-reviewed articles supporting MPP’s work.

→ The Lancet, Accelerating pooled licensing of medicines to enhance global production and equitable access

→ The Lancet Public Health, The ecosystem of health decision making: from fragmentation to synergy

→ Cambridge University Press, Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries

→ The Review of Economic and Statistics, Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool

→ Journal of Health Economics, Global drug diffusion and innovation with the medicines patent pool
At MPP we are proud and passionate about the values that shape our work and who we are. These values drive our professionalism in the workplace, and are summarised in the four headings below.

**RESPECT**
We celebrate diversity, equity and inclusion in all aspects of our mission. We honour our commitments. We seek and acknowledge the contribution of collaborating partners and celebrate the collective impact of partnerships.

**GENEROSITY**
We communicate and proactively share relevant information in a timely and appropriate manner. We provide our partners with the support they need to succeed in achieving common goals. We are generous with our time and our expertise.

**COMMITMENT**
We are dedicated to improving global public health over competing interests. We are accountable for our actions and set ambitious goals and clear expectations of what constitutes success. We work with integrity and diligence to achieve our goals.

**COURAGE**
We encourage initiative and we explore and forge innovative paths. We voice our opinions and suggest ideas openly. We listen to and acknowledge people’s varied opinions in a receptive manner. We question our underlying assumptions; we have the courage to take risks and accept failure. We encourage our partners to hold us accountable to our commitments.
Focus on the future

In 2022, MPP worked on its new strategy, taking time to review our work with both board and with staff, fully developing our new approach.

If we are to fulfil our ambition of greater access to life-saving medicines and technologies for those living in low- and middle-income countries. Our Strategy 2023-2025, approved in December 2022 by our board, lays down the direction and focus for this ambition.

Five crucial dimensions will guide our work, defining where and how MPP fulfils its mandate.

1. Diseases and indications
   - We will target disease areas where we have already achieved impact, and new areas where licensing could contribute to affordable access.

2. Health tools and technologies
   - We will strengthen our focus on more complex technologies that cover long-acting formulations, mRNA vaccines and biologics.

3. Breadth and scope of licences
   - MPP’s licensing standards are internationally recognised as the most transparent and access-friendly in the global health sector. We will continue to explore ways to enable more people in LMICs to benefit from our licences, adapting them to other disease areas and complex technologies.

4. Product lifecycles
   - We will explore licensing upstream to further reduce the time from product approval to affordable access, and continue supporting downstream access in LMICs.

5. Our spectrum of activities and services
   - We will support an enabling environment for licensing, negotiate licences and technology transfer agreements that facilitate the development of affordable health products, map key patents and foster strategic partnerships for access.

The following five goals underpin this strategic direction:

GOAL 01
EXPAND ACCESS TO INNOVATIVE MEDICINES FOR INFECTIOUS DISEASES focusing on HIV, tuberculosis (TB), viral hepatitis, and other infectious diseases where MPP’s licensing can contribute to the public health response.

GOAL 02
ESTABLISH VOLUNTARY LICENSING AS AN IMPACTFUL ACCESS MECHANISM FOR OTHER DISEASES AND CONDITIONS in non-communicable diseases and maternal health.

GOAL 03
FACILITATE DEVELOPMENT AND ACCESS TO NOVEL MEDICAL TECHNOLOGIES including long-acting technologies, biologics, and mRNA vaccines.

GOAL 04
ACCELERATE EQUITABLE ACCESS TO COUNTERMEASURES FOR PANDEMICS AND OTHER INTERNATIONAL HEALTH EMERGENCIES by contributing to the COVID-19 response and positioning MPP in the context of future pandemic preparedness and response (PPR) architecture.

GOAL 05
SUPPORT DIVERSIFIED AND SUSTAINABLE MANUFACTURING CAPACITY by contributing to local/regional production and engaging in technology transfer, particularly for some of the more complex products on which MPP is working.
Our strategy for 2023-2025 lays out our plans to

- Establish 10 new licences
- Support 10 technology transfers
- Develop 5 new products

Now MPP moves into an exciting new phase

By 2025

- 30M people will be accessing MPP-licensed products each year up from 15 million annually
- This means that close to 90M patient-years of products will be supplied by MPP licensees, creating savings of more than 1.2 USD billion for the global community in this period alone

It is expected that over this period, MPP’s licences will enable:

- 30 million people annually to benefit from access to health products licensed by MPP and contribute to saving USD 1.2 billion from the procurement of more affordable treatments

VISION

A world in which people in need in low- and middle-income countries (LMICs) have rapid access to effective and affordable medical treatments and health technologies.

MISSION

Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.

PRIORIT Y AREAS OF WORK

Core activities

- Developing an enabling environment
- In-licensing
- Patents
- Patent mapping
- Supporting development & transfer of technology
- Supporting access

Enablers

- Resource development
- Organisational effectiveness
- Review & learning

TARGETS

10 new licences concluded
5 new products developed
10 vaccine manufacturers have received one or more mRNA technology transfers and products
Unitaid founded the Medicines Patent Pool in 2010 to address the challenges in access to essential medicines in low- and middle-income countries. Unitaid is involved in finding new ways to prevent, treat and diagnose HIV/AIDS, TB, and malaria more quickly, affordably and more effectively. It finds and transforms game-changing ideas into workable solutions that can help accelerate the end of these three diseases. MPP is important in implementing Unitaid’s objectives by working with a range of organisations to license key medicines for generic manufacture. Unitaid serves now as MPP’s sole funder for its HIV, hepatitis C and TB activities.

France funds MPP’s expansion into technology transfer. Its support allows MPP to co-lead the mRNA Technology Transfer Programme with WHO to increase sustainable local production of mRNA vaccines and ensure health security. It will also enable MPP to offer the needed technology transfer support to generic companies when MPP receives licences for biologic therapeutics.

The Ministry of Foreign Affairs of Japan is a major contributor to MPP’s COVID-19 work. Supporting rapid access to affordable health technologies to end the pandemic, Japan’s support allows MPP to explore opportunities for COVID-19 health technologies and to facilitate access, working towards securing access-oriented licences that will benefit those in need, particularly in low- and middle-income countries.

The Swiss Agency for Development and Cooperation (SDC) is engaged in the area of health in low- and middle-income countries and transition countries. With actions revolving around three issues: the strengthening of health systems; the fight against communicable and non-communicable diseases; and the improvement of sexual, reproductive, maternal, neonatal and child health. The SDC provides funding for MPP to implement its mandate expansion into patented essential medicines on the WHO’s Essential Medicines List, and those with strong potential for future inclusion, including in COVID-19.

The German Agency for International Cooperation contributes to MPP’s intellectual property work. Supporting understanding of intellectual property for COVID-19 vaccines as well as technologies needed for the mRNA Technology Transfer Programme. Germany’s support allows MPP to provide VaxPat, a patent database devoted to COVID-19 vaccines worldwide. The patent information on COVID-19 vaccines is compiled for the purpose of providing greater transparency on patents relating to key COVID-19 vaccines.
Governance

**MPP GOVERNANCE BOARD IN 2022**

Marie-Paule Kieny – Chair of Governance

---

**GOVERNANCE BOARD**

Manica Balasegaram until 31 December 2022
Patrizia Carlevaro until 30 June 2022
Mojisola Christianah Adeyeye until 30 June 2022
John-Arne Røttingen – Board Member
Peter Maybarduk – Board Member
Alexandra Volgina – Board Member
Max Santa Cruz – Board Member
Pushpa Vijayaraghavan – Board Member

---

**NON-VOTING PARTICIPANTS**

Philippe Duneton – Founder and principal funder, UNITAID
Mariangela Batista Galvão Simão – World Health Organization
Amy Dietterich – World Intellectual Property Organization
Antony Scott Taubman – World Trade Organization

---

**MPP EXPERT ADVISORY GROUP IN 2022**

Peter Beyer – Chair

---

**MPP SCIENTIFIC ADVISORY PANEL IN 2022**

Grania Bridgen
Samson Kiware
Iheanyi Okpala
Nicola Magrini
Gavin Giovannoni
François Venter
Nagalingeswaran Kumarasamy
Chloe Orkin
Pedro Cahn
Nabil Haddad
Marc Blockman
Anthony Oyekunle
Sylvia Kehlenbrink

---

Ellen ‘t Hoen
Jan Gheuens until Sept. 2022
Zeba Aziz until Sept. 2022
Fatima Suleman
Martha Gyansa-Lutterodt
Jordan Jarvis

Giten Khwairakpam
Akthem Fourati until July 2022
Valerie Paris
Manuel Gonçalves
Deus Mubangizi
Jennifer Cohn
Carlos Correa joined Oct. 2022
### MPP Staff in 2022

#### Operations and Resources
- **Karine Belondrade**: Head of Strategy, Operations and Resource Mobilisation
- **Razan Walch Mahmoud**: Paralegal Officer
- **Chan Park**: Legal Counsel
- **Andrew Spencer**: Associate Counsel

#### Technology Transfer
- **Landry Bertaux**: Expert, Biologic Health Products
- **Cristina Bruno**: Project Manager - Technology Transfer
- **Jie Mames**: Head of Technology Transfer
- **Monica Moschioni**: Programme Manager - Technology Transfer

#### Legal
- **Kelvin Nguyen**: Associate Counsel from May 2022
- **Nataliya Omelchuk**: Senior Associate Counsel until June 2022
- **Razan Walch Mahmoud**: Paralegal Officer from September 2022
- **Chan Park**: Legal Counsel from August 2022
- **Andrew Spencer**: Associate Counsel until January 2022

#### Communications
- **Shania Khan**: Communications Manager from April 2022
- **Gelise McCullough**: Head of Communications from March 2022
- **Valentina Ndelbalema**: Digital Communications Officer from May 2022
- **Sophie Thienvenaz**: Senior Communications Manager from November 2022
- **Olivier Uzel**: Partnerships and Media Relations Manager from January 2022
- **Betina Zago**: Communications Officer until January 2022

#### Business Development - India Liaison Office
- **Aditi Das**: Senior Manager - Technical Liaison Office until October 2022
- **Meghmala Das**: Alliance Manager - Business Development
- **Abhijeet Moore**: Alliance Manager - Business Development
- **Rajesh Murthy**: Head of India Office Operations
- **Maneesha Renaut**: Project Manager - Business Development
- **Prijanka Vagal**: Administrative Officer India Liaison Office from March 2022
- **Ashok Valecha**: Alliance Manager - Business Development from March 2022

#### Business Development
- **Marco Casalini**: Alliance Manager - Business Development until October 2022
- **Lobna Gaayeb**: Head of Scientific and Medical Information
- **Nicola Loffredi**: Alliance Manager - Business Development
- **Hannah Moak**: Business Development Manager - In-licensing until August 2022
- **Kim Mtwamela**: Scientific Manager
- **Parag Nimbolkar**: Business Development Manager - In-licensing from May 2022
- **Sandra Nobre**: Head of Business Development
- **Manuele Piccolis**: Senior Manager - Scientific and Medical Information

#### Policy Advocacy & Market Access
- **Joshua Anandaraj**: Patent Information Manager from October 2022
- **Tiwadayo Braimoh**: Policy and Advocacy Manager from February 2022
- **Esteban Burrone**: Head of Strategy, Policy and Market Access
- **Amina Larbi**: Head of Patent Information from March 2022
- **Marie Levy**: Policy and Advocacy Officer from October 2022
- **Liudmila Maistat**: Policy and Advocacy Manager
- **Sébastien Morin**: Policy and Advocacy Manager from March 2022
- **Giulia Segafredo**: Market Access Manager from September 2022
- **Zongyuan Tang**: Patent Information Officer from March 2022

#### Operations and Resources
- **Karine Belondrade**: Head of Strategy, Operations and Resource Mobilisation until June 2022
- **Gerry Bernard**: Finance and Administration Officer from March 2022
- **Jane Caldwell**: Head of Operations and Resources from August 2022
- **Vincent Chauvin**: Chief Financial Officer and Head of Human Resources until May 2022
- **Viktoria Dovgan**: Office Manager from May 2022
- **Mushta Duale**: Finance and Administration Officer May only
- **Robin Eede**: Finance Manager until September 2022
- **Ruth Foley**: Monitoring and Evaluation Manager until September 2022
- **Muriel Lacombe**: Finance Manager
- **Sophie Naeye**: Office Manager from September 2022
- **Malgorzata Stehle**: Human Resources Manager from September 2022
- **Agnese Tonnina**: Grants and Operations Manager

#### Communications
- **Shania Khan**: Communications Manager from April 2022
- **Gelise McCullough**: Head of Communications from March 2022
- **Valentina Ndelbalema**: Digital Communications Officer from May 2022
- **Sophie Thienvenaz**: Senior Communications Manager from November 2022
- **Olivier Uzel**: Partnerships and Media Relations Manager from November 2022
- **Betina Zago**: Communications Officer until January 2022
To the Governance Board of Medicines Patent Pool Foundation, Geneva

Geneva, 16 May 2023

Report of the statutory auditor

Report on the audit of the financial statements

Opinion
We have audited the financial statements of Medicines Patent Pool Foundation, Geneva (the Foundation), which comprise the balance sheet as at 31 December 2022, the statement of operations, the statement of cash flows and the statement of change in capital for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position as at 31 December 2022 and of its result of operations and its cash flows for the year then ended in accordance with Swiss GAAP FER (Core FER) and comply with Swiss law and the deed of the foundation.

Basis for opinion
We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the “Auditor's responsibilities for the audit of the financial statements” section of our report. We are independent of the Foundation in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information
The Board of Governance is responsible for the other information. The other information comprises the information included in the annual report but does not include the financial statements and our auditor’s report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Governance Board's responsibilities for the financial statements
The Board of Governance is responsible for the preparation of the financial statements, which give a true and fair view in accordance with Swiss GAAP FER (Core FER), the provisions of Swiss law and the deed of foundation, and for such internal control as the Board of Governance determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Governance is responsible for assessing the Foundation’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Governance either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on EXPERTsuisse’s website at: https://www.expertsuisse.ch/en/audit-report. This description forms an integral part of our report.

Report on other legal and regulatory requirements
In accordance with Art. 83b para. 3 CC in conjunction with Art. 728a para. 1 item 3 CO and PS-CH 880, we confirm that an internal control system exists, which has been designed for the preparation of the financial statements according to the instructions of the Board of Governance.

We recommend that the financial statements submitted to you be approved.

Ernst & Young Ltd
Licensed audit expert
(Auditor in charge)

Enclosures
- Financial statements (balance sheet, statement of operations, cash flow statement, statement of changes in capital and notes)
### Balance Sheet as of December 31st, 2022

**Meditines Patent Pool Foundation**

**Statement of operations for the period from January 1st, to December 31st, 2022**

*Expressed in Swiss Francs*

#### Income

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donations</td>
<td>18'982'718</td>
<td>22'849'078</td>
</tr>
<tr>
<td>Other income</td>
<td>11'512</td>
<td>9'800</td>
</tr>
<tr>
<td><strong>TOTAL OPERATING INCOME</strong></td>
<td><strong>18'994'029</strong></td>
<td><strong>22'858'878</strong></td>
</tr>
</tbody>
</table>

#### Operating Expenditure

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel costs and social charges</td>
<td>5'815'565</td>
<td>4'947'645</td>
</tr>
<tr>
<td>Other personnel costs</td>
<td>11'312</td>
<td>9'800</td>
</tr>
<tr>
<td><strong>TOTAL PERSONNEL COSTS</strong></td>
<td><strong>18'994'029</strong></td>
<td><strong>22'858'878</strong></td>
</tr>
</tbody>
</table>

#### Administrative Expenditure

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional fees</td>
<td>2'066'023</td>
<td>1'851'575</td>
</tr>
<tr>
<td>Rent</td>
<td>338'774</td>
<td>330'318</td>
</tr>
<tr>
<td>General and administrative costs</td>
<td>107'918</td>
<td>93'436</td>
</tr>
<tr>
<td>IT services and maintenance</td>
<td>429'445</td>
<td>242'753</td>
</tr>
<tr>
<td>Marketing and Advertising</td>
<td>57'750</td>
<td>27'148</td>
</tr>
<tr>
<td>Travel and representation costs</td>
<td>803'601</td>
<td>115'730</td>
</tr>
<tr>
<td>Depreciation of tangible assets</td>
<td>51'363</td>
<td>34'827</td>
</tr>
<tr>
<td><strong>TOTAL ADMINISTRATIVE EXPENDITURE</strong></td>
<td><strong>3'854'874</strong></td>
<td><strong>2'695'787</strong></td>
</tr>
</tbody>
</table>

#### Sub-Grant Expenditure

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sub-grants</td>
<td>3e 9'237'559</td>
<td>1'404'298</td>
</tr>
<tr>
<td><strong>TOTAL SUB-GRANT EXPENDITURE</strong></td>
<td><strong>9'237'559</strong></td>
<td><strong>1'404'298</strong></td>
</tr>
</tbody>
</table>

#### Financial results

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total surplus / (deficit) prior to allocations</td>
<td>58'733</td>
<td>13'477'573</td>
</tr>
<tr>
<td>Financial result surplus / (deficit)</td>
<td>11 91'057</td>
<td>(282'286)</td>
</tr>
<tr>
<td><strong>TOTAL SURPLUS / (DEFICIT) AFTER ALLOCATIONS</strong></td>
<td><strong>58'733</strong></td>
<td><strong>13'477'573</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Allocation to) / use from restricted capital funds</td>
<td>(27'221)</td>
<td>(13'427'700)</td>
</tr>
<tr>
<td>(Allocation to) / use from unrestricted capital funds</td>
<td>(31'512)</td>
<td>(49'873)</td>
</tr>
</tbody>
</table>

#### Assets

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash and cash equivalent</strong></td>
<td>84'594'518</td>
<td>15'839'214</td>
</tr>
<tr>
<td>Donors receivable</td>
<td>6 729'779</td>
<td>6'793'570</td>
</tr>
<tr>
<td>Other receivable</td>
<td>52'367</td>
<td>41'258</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>5 23'214'827</td>
<td>729'547</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>114'591'491</td>
<td>23'403'589</td>
</tr>
<tr>
<td><strong>Non-current assets</strong></td>
<td>42'244'938</td>
<td>17'936'251</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>156'836'429</td>
<td>41'339'840</td>
</tr>
</tbody>
</table>

#### Liabilities, Funds and Capital

<table>
<thead>
<tr>
<th>Liabilities, Funds and Capital</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable</td>
<td>679'084</td>
<td>533'114</td>
</tr>
<tr>
<td>Subgrants payable</td>
<td>14'911'099</td>
<td>0</td>
</tr>
<tr>
<td>Accrued liabilities</td>
<td>86'551</td>
<td>80'273</td>
</tr>
<tr>
<td>Provisions</td>
<td>8 260'630</td>
<td>340'130</td>
</tr>
<tr>
<td>Deferred income</td>
<td>9 12'412'953</td>
<td>679'570</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td><strong>28'350'115</strong></td>
<td><strong>7'747'086</strong></td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td>112'599'103</td>
<td>17'764'276</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>140'949'219</td>
<td>25'511'362</td>
</tr>
<tr>
<td><strong>Restricted Funds</strong></td>
<td>15'727'605</td>
<td>15'700'384</td>
</tr>
<tr>
<td><strong>TOTAL RESTRICTED FUNDS</strong></td>
<td>15'727'605</td>
<td>15'700'384</td>
</tr>
<tr>
<td><strong>Capital</strong></td>
<td>50'000</td>
<td>50'000</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL OF THE FOUNDATION</strong></td>
<td><strong>159'606</strong></td>
<td><strong>128'094</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES, FUNDS AND CAPITAL</strong></td>
<td><strong>156'836'429</strong></td>
<td><strong>41'339'840</strong></td>
</tr>
</tbody>
</table>
Statement of Cash Flow for the period from January 1st, to December 31st, 2022  
Expressed in Swiss Francs

**CASH FLOWS FROM OPERATING ACTIVITIES**

<table>
<thead>
<tr>
<th>NOTES</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Surplus / (Deficit) prior to allocations</td>
<td>58’733</td>
<td>17’477’573</td>
</tr>
<tr>
<td>Depreciation and impairment</td>
<td>35’088</td>
<td>34’826</td>
</tr>
<tr>
<td>(Decrease) / Increase in Provisions</td>
<td>8 (7’955’803)</td>
<td>1’070’802</td>
</tr>
<tr>
<td>(Increase) / Decrease in Other receivables</td>
<td>(11’109)</td>
<td>(5’782)</td>
</tr>
<tr>
<td>Decrease / (Increase) in Donors receivable</td>
<td>5’955’803</td>
<td>6’976’729</td>
</tr>
<tr>
<td>(Decrease) / Increase in Prepaid expenses</td>
<td>(7’574’181)</td>
<td>(561’706)</td>
</tr>
<tr>
<td>(Increase) / Decrease in Deferred expenses</td>
<td>(44’848’216)</td>
<td>–</td>
</tr>
<tr>
<td>Increase / (Decrease) in Accounts payable</td>
<td>5’955’803</td>
<td>6’976’729</td>
</tr>
<tr>
<td>Decrease / (Increase) in Donors receivable</td>
<td>4’449’185</td>
<td>76’141</td>
</tr>
<tr>
<td>Increase / (Decrease) in Prepaid expenses</td>
<td>70’517’094</td>
<td>(6’976’729)</td>
</tr>
<tr>
<td>Decrease / (Increase) in Donors receivable</td>
<td>6’078</td>
<td>58’236</td>
</tr>
</tbody>
</table>

**NET CASH PROVIDED (USED) BY OPERATING**

| 69’053’976 | 13’250’091 |

**CASH FLOW FROM INVESTING ACTIVITIES**

| Decrease / (Increase) of long term receivable | 2’248 | (477) |
| Acquisition of tangible fixed assets | 2’248 | (477) |
| Disposals of tangible fixed assets | 68’517 | – |

**NET CASH USED IN INVESTING ACTIVITIES**

| (298’672) | (52’918) |

**CASH FLOW FROM FINANCING ACTIVITIES**

| Translation ajustement | – | – |
| translation ajustement | – | – |

**NET CHANGE IN CASH**

| 68’755’304 | 13’197’173 |

**CASH AND CASH EQUIVALENTS**

| At the beginning of the fiscal year | 15’839’214 | 2’642’040 |
| At the end of the fiscal year | 84’594’518 | 15’839’214 |

**NET CHANGE IN CASH**

| 68’755’304 | 13’197’173 |

---

**Statement of changes in Capital**

**RESTRICTED FUNDS**

<table>
<thead>
<tr>
<th>BEGINNING OF THE PERIOD (01.01.2022)</th>
<th>ALLOCATION OF FUNDS</th>
<th>USE OF FUNDS</th>
<th>ADJUST</th>
<th>END OF THE PERIOD (31.12.2022)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNITAID MPPS - UTD3 (Core activities HIV TB HEPC)</td>
<td>3’688’118</td>
<td>5’160’689 (’261’838)</td>
<td>–</td>
<td>3’386’969</td>
</tr>
<tr>
<td>Swiss Agency for Cooperation and Development - SDC 3 (Expansion activities)</td>
<td>212’631</td>
<td>300’000 (321’631)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>World Health Organisation - WHO (GIZ - Patent landscaping activities)</td>
<td>–</td>
<td>288’692 (288’692)</td>
<td>(970’338)</td>
<td>–</td>
</tr>
<tr>
<td>(GAP - Implementation of project)</td>
<td>–</td>
<td>70’535</td>
<td>(23’820)</td>
<td>–</td>
</tr>
<tr>
<td>Government of Canada* SUBGRANTS (Transfers to the Tech Transfer HUB)</td>
<td>–</td>
<td>581’429</td>
<td>–</td>
<td>581’429</td>
</tr>
<tr>
<td>Government of Norway SUBGRANTS (Transfers to the Tech Transfer HUB)</td>
<td>–</td>
<td>4’106’680 (’106’680)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government of Japan (COVID 19 activities)</td>
<td>240’428</td>
<td>158’867 (399’295)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government of France MPP (Support to the Tech Transfer HUB) SUBGRANTS (Transfers to the Tech Transfer HUB)</td>
<td>4’154’982</td>
<td>3’188’897 (’188’897)</td>
<td>–</td>
<td>4’154’982</td>
</tr>
<tr>
<td>–</td>
<td>7’404’225</td>
<td>4’784’735</td>
<td>(3’188’897)</td>
<td>–</td>
</tr>
<tr>
<td>TOTAL RESTRICTED FUNDS</td>
<td>15’700’384</td>
<td>18’982’718 (19’566’926)</td>
<td>581’429</td>
<td>15’727’605</td>
</tr>
</tbody>
</table>

**CAPITAL**

| Paid-in capital | 50’000 | – | – | 50’000 |
| Unrestricted funds | 78’094 | 31’512 | – | 109’606 |

**TOTAL CAPITAL OF THE FOUNDATION**

| 128’094 | 31’512 | – | 159’606 |

*NOTE 1: GOVERNMENT OF CANADA FOREIGN EXCHANGE*

Whilst there have been no expenses during 2022, there was a foreign exchange gain upon receipt of the Government of Canada.

**RESTRICTED FUNDS**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNITAID MPPS - UTD3 (Core activities HIV TB HEPC)</td>
<td>2’179’430</td>
<td>6’922’843 (5’414’156)</td>
<td>–</td>
<td>3’688’118</td>
</tr>
<tr>
<td>Swiss Agency for Cooperation and Development - SDC 3 (Expansion activities)</td>
<td>93’252</td>
<td>552’000 (431’621)</td>
<td>–</td>
<td>212’631</td>
</tr>
<tr>
<td>Government of Japan (COVID 19 activities)</td>
<td>–</td>
<td>9’137’100 (673’282)</td>
<td>–</td>
<td>240’428</td>
</tr>
<tr>
<td>Government of France MPP (Support to the Tech Transfer HUB) SUBGRANTS (Transfers to the Tech Transfer HUB)</td>
<td>4’154’982</td>
<td>9’120’775 (’100’775)</td>
<td>–</td>
<td>4’154’982</td>
</tr>
<tr>
<td>–</td>
<td>7’404’225</td>
<td>7’404’225</td>
<td>–</td>
<td>7’404’225</td>
</tr>
<tr>
<td>TOTAL RESTRICTED FUNDS</td>
<td>2’272’683</td>
<td>22’849’078 (7’411’377)</td>
<td>–</td>
<td>15’700’384</td>
</tr>
</tbody>
</table>

**CAPITAL**

| Paid-in capital | 50’000 | – | – | 50’000 |
| Unrestricted funds | 78’094 | 49’873 | – | 128’094 |

**TOTAL CAPITAL OF THE FOUNDATION**

| 128’094 | 49’873 | – | 177’967 |
NOTE 2 : PRESENTATION

The organisation's full name is "Medicines Patent Pool Foundation". It is registered in Geneva, Switzerland and is known as MPP. MPP is a Foundation under the Swiss Civil Code and has signed in February 2018 a "seat agreement" with the Swiss Confederation granting to the Foundation the status of "Other International Organisation".

The purpose of the Foundation is to improve health by providing patients in low and middle income countries with increased access to quality, safe, efficacious, more appropriate and more affordable health products, including through a voluntary patent pool mechanism.

The financial statements of the Foundation reflect 100% of the Geneva Headquarter activities as well as 100% of the activities conducted by the MPP Indian Liaison Office.

The audited financial statements are publicly available on MPP’s website here: https://medicinespatentpool.org/who-we-are/annual-reports. The Foundation Governance Board has validated the 2022 financial statements on May 16th, 2023.

Statement of operations transactions are recorded in Swiss Francs at the date of transaction.

d – REVENUE RECOGNITION

Revenue is recognised when it is probable that the economic benefits associated with the transaction will inure to MPP and can be reliably estimated, upon receipt of a written confirmation or agreement from the donor.

MPP is receiving two types of donation: yearly donation related to the fiscal year and multi-years donation covering several years.

Donations are recognised in the statement of operations once they definitely belong to MPP. They are considered as unrestricted funds, unless the donor stipulates a specific restriction. With multi-year grants, if the donor does not specifically determine the yearly utilisation, revenue is recognised against the expenses incurred.

When the use of funds are restricts to specific activities, the donation is considered to be an allocated fund. Allocated funds not used at year-end are presented in a specific section of the balance sheet.

Donations designated for use after the reporting date are reported as a deferred income in the financial statements and recognised as revenue in the year designated by the donor.

Donations that will fall due after five years or are estimated as unlikely to be paid are not accounted for and are disclosed as contingent assets owing to uncertainties associated with their receipt. In 2021 and 2022, no donations were considered contingent assets.

MEDICINES PATENT POOL FOUNDATION, GENEVA

Notes to the financial statements as of December 31st, 2022
(with December 31st, 2021 comparative figures)
Expressed in Swiss Francs

NOTE 3 : SIGNIFICANT ACCOUNTING POLICIES

a – STATEMENTS OF COMPLIANCE

The MPP financial statements include the balance sheet, statement of operations, statements of changes in capital, statement of cash flows, and notes to the financial statements.

b – BASIS OF PRESENTATION FOR PREPARING THE FINANCIAL STATEMENTS

The financial statements of the Foundation have been prepared in accordance with the statutes of the Foundation, the provisions of the Swiss Code of Obligations (Art. 957 to 963b) and the Swiss Generally Accepted Accounting Principles (Swiss GAAP FER/RPC including Swiss Gaap FER/RPC 21).

The Financial Statements are presented in Swiss Francs ("CHF") unless otherwise stated. All amounts are rounded to the nearest Swiss Franc with the consequence that the rounded amounts may not add to the rounded total in all cases.

The financial statements have been prepared using historical cost principles and are based on the assumptions that the going concern is possible for the foreseeable future.

c – TRANSLATION OF OPERATIONS IN FOREIGN CURRENCY

Open balances in currencies other than Swiss francs are converted into Swiss Francs at the year-end rate as follows:

<table>
<thead>
<tr>
<th>Currency</th>
<th>Exchange Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>USD</td>
<td>0.923573</td>
</tr>
<tr>
<td>INR</td>
<td>0.011164</td>
</tr>
<tr>
<td>EUR</td>
<td>0.984849</td>
</tr>
<tr>
<td>ZAR</td>
<td>0.054425</td>
</tr>
</tbody>
</table>

Statement of operations transactions are recorded in Swiss Francs at the date of transaction.

MEDICINES PATENT POOL FOUNDATION, GENEVA

Notes to the financial statements as of December 31st, 2022
(with December 31st, 2021 comparative figures)
Expressed in Swiss Francs
NOTE 4 : DONORS RECEIVABLE

Donors receivable come from contractual commitment signed with donors. The current donors receivable amount include the commitment up to one year and the non-current donors receivable amount include the commitment above one year.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO</td>
<td>175'038 CHF</td>
<td>552'000 CHF</td>
</tr>
<tr>
<td>GIZ (111'307 EUR)</td>
<td>111'295 CHF</td>
<td>98'485 CHF</td>
</tr>
<tr>
<td>Belgium (100'000 EUR)</td>
<td>111'295 CHF</td>
<td>98'485 CHF</td>
</tr>
<tr>
<td>Unitaid (6'869'320 USD)</td>
<td>6'544'961</td>
<td>6'341'570</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT DONORS RECEIVABLE</strong></td>
<td>6'729'779</td>
<td>6'793'570</td>
</tr>
<tr>
<td>Unitaid (12'853'407 USD)</td>
<td>11'872'265</td>
<td>17'589'238</td>
</tr>
<tr>
<td>SDC (1'75'038 CHF)</td>
<td>1'75'038 CHF</td>
<td>1'75'038 CHF</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT DONORS RECEIVABLE</strong></td>
<td>13'872'265</td>
<td>17'764'276</td>
</tr>
</tbody>
</table>

There were no provision on donors receivable, either in 2022 or in 2021.

e – SUB-GRANTS

Sub-grants are governed by a written agreement and disbursements are phased over the lifetime of the project. Sub-grants are recognized as a current period pre-payment upon disbursement and subsequently recognized as an expense upon the submission of a quarterly financial and an activity report which details the amount spent during the period and the future forecast. Upon receipt of this report the internal MPP team review and validate the expenses and authorise the next disbursement. The difference between the amount disbursed and the total award is in deferred expenditure.

f – FIXED ASSETS

The fixed assets are valued at historical cost of acquisition, less the accumulated depreciation. The depreciation is recognized on the straight-line method over the useful life, as follows:

<table>
<thead>
<tr>
<th>CATEGORY OF FIXED ASSETS</th>
<th>USEFUL LIFE (YEARS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office equipment</td>
<td>8 years</td>
</tr>
<tr>
<td>IT infrastructure</td>
<td>3 years</td>
</tr>
<tr>
<td>Leasehold improvement</td>
<td>5 years</td>
</tr>
</tbody>
</table>

g – ACCRUED LIABILITIES

This position includes the charges related to the current exercise that will be paid the following exercise.

h – TAXES

Thanks to the seat agreement signed in February 2018, MPP is not subject to any taxation in Switzerland. This exemption only relates to Swiss activities. The Indian Liaison office is subject to all local taxes such as VAT.
**NOTE 5 : PREPAID AND DEFERRED EXPENSES**

**SHORT TERM**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
<tr>
<td><strong>SUB TOTAL</strong></td>
<td>23'214'827</td>
<td>729'547</td>
</tr>
</tbody>
</table>

**LONG TERM**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen (21'688'515 USD)</td>
<td>20'026'611</td>
<td>–</td>
</tr>
<tr>
<td>Afrigen (7'431'815 ZAR)</td>
<td>404'476</td>
<td>–</td>
</tr>
<tr>
<td>Biovac (165'795'965 ZAR)</td>
<td>9'021'486</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC (8,866,667 ZAR)</td>
<td>482'568</td>
<td>–</td>
</tr>
<tr>
<td><strong>SUB TOTAL</strong></td>
<td>29'937'116</td>
<td>–</td>
</tr>
</tbody>
</table>

**NET VALUE AS OF 31.12.2022**

<table>
<thead>
<tr>
<th>OFFICE EQUIPMENT</th>
<th>INFRASTRUCT.</th>
<th>LEASEHOLD IMPROVEMENT</th>
<th><strong>TOTAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>44'130</td>
<td>47'601</td>
<td>91'732</td>
</tr>
</tbody>
</table>

**NET VALUE AS OF 01.01.2021**

<table>
<thead>
<tr>
<th>OFFICE EQUIPMENT</th>
<th>INFRASTRUCT.</th>
<th>LEASEHOLD IMPROVEMENT</th>
<th><strong>TOTAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>43'152</td>
<td>29'415</td>
<td>72'567</td>
</tr>
</tbody>
</table>

**GROSS VALUE**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
</tbody>
</table>

**ACUMULATED DEPRECIATION**

Afrigen is a sub-grantee in South-Africa financed in 2022 through the funding granted by the Governments of France, Canada and Norway.

Biovac is a sub-grantee in South-Africa financed in 2022 through the funding granted by the Governments of France, Canada and Norway.

SAMRC is a sub-grantee in South-Africa financed in 2022 through the funding granted by the Governments of France, Canada and Norway.

Notes to the financial statements as of December 31st, 2022

Expressed in Swiss Francs

**NOTE 6 : FIXED ASSETS**

**OFFICE EQUIPMENT**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
<tr>
<td><strong>SUB TOTAL</strong></td>
<td>23'214'827</td>
<td>729'547</td>
</tr>
</tbody>
</table>

**IT**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>44'130</td>
<td>47'601</td>
</tr>
<tr>
<td>Biovac</td>
<td>26'043</td>
<td>48'446</td>
</tr>
<tr>
<td>SAMRC</td>
<td>(67'357)</td>
<td>(1'157)</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>240'002</td>
<td>64'239</td>
</tr>
</tbody>
</table>

**INFRASTRUCT.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
<tr>
<td><strong>SUB TOTAL</strong></td>
<td>23'214'827</td>
<td>729'547</td>
</tr>
</tbody>
</table>

**LEASEHOLD IMPROVEMENT**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>44'130</td>
<td>47'601</td>
</tr>
</tbody>
</table>

**NET VALUE AS OF 31.12.2022**

<table>
<thead>
<tr>
<th>OFFICE EQUIPMENT</th>
<th>INFRASTRUCT.</th>
<th>LEASEHOLD IMPROVEMENT</th>
<th><strong>TOTAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>44'130</td>
<td>47'601</td>
<td>91'732</td>
</tr>
</tbody>
</table>

**TOTAL**

<table>
<thead>
<tr>
<th>OFFICE EQUIPMENT</th>
<th>INFRASTRUCT.</th>
<th>LEASEHOLD IMPROVEMENT</th>
<th><strong>TOTAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>43'152</td>
<td>29'415</td>
<td>72'567</td>
</tr>
</tbody>
</table>

**GROSS VALUE**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
</tbody>
</table>

**ACCUMULATED DEPRECIATION**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>14'661'117</td>
<td>547'329</td>
</tr>
<tr>
<td>Biovac</td>
<td>7'430'467</td>
<td>–</td>
</tr>
<tr>
<td>SAMRC</td>
<td>965'177</td>
<td>–</td>
</tr>
<tr>
<td>Other prepaid expenses</td>
<td>158'067</td>
<td>182'218</td>
</tr>
</tbody>
</table>

**NET VALUE AS OF 01.01.2021**

<table>
<thead>
<tr>
<th>OFFICE EQUIPMENT</th>
<th>INFRASTRUCT.</th>
<th>LEASEHOLD IMPROVEMENT</th>
<th><strong>TOTAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrigen</td>
<td>43'152</td>
<td>29'415</td>
<td>72'567</td>
</tr>
</tbody>
</table>

**Notes to the financial statements as of December 31st, 2022**

Expressed in Swiss Francs
NOTE 7: FINANCIAL ASSETS

Financial assets consist of rental deposits for the Head office and Indian office.

NOTE 8: PROVISIONS

<table>
<thead>
<tr>
<th></th>
<th>UNTAKEN VACATIONS</th>
<th>FINANCIAL REWARD TO STAFF</th>
<th>OTHERS</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at 01.01.2022</td>
<td>217'900</td>
<td>108'750</td>
<td>13'479</td>
<td>340'129</td>
</tr>
<tr>
<td>Additional provisions</td>
<td>42'730</td>
<td></td>
<td></td>
<td>42'730</td>
</tr>
<tr>
<td>Amounts used</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(108'750)</td>
<td></td>
<td>(13'479)</td>
<td>(122'229)</td>
</tr>
<tr>
<td><strong>BALANCE AT 31.12.2022</strong></td>
<td><strong>260'630</strong></td>
<td></td>
<td></td>
<td><strong>260'630</strong></td>
</tr>
<tr>
<td>Balance as of 01.01.2021</td>
<td>147'846</td>
<td></td>
<td></td>
<td>169'327</td>
</tr>
<tr>
<td>Additional provisions</td>
<td>70'054</td>
<td></td>
<td></td>
<td>197'284</td>
</tr>
<tr>
<td>Amounts used</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(21'181)</td>
<td></td>
<td>(21'181)</td>
</tr>
<tr>
<td>Unused amounts reversed</td>
<td></td>
<td></td>
<td></td>
<td>(300)</td>
</tr>
<tr>
<td><strong>BALANCE AS OF 31.12.2021</strong></td>
<td><strong>217'900</strong></td>
<td></td>
<td></td>
<td><strong>340'129</strong></td>
</tr>
</tbody>
</table>

NOTE 9: DEFERRED INCOME

### SHORT TERM

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SDC</td>
<td>(175'038)</td>
<td>(552'000)</td>
</tr>
<tr>
<td>UNITAID (6'869'320 USD)</td>
<td>(6'342'925)</td>
<td>(6'241'570)</td>
</tr>
<tr>
<td>WHO (GIZ) (853'250 EUR)</td>
<td>(889'673)</td>
<td></td>
</tr>
<tr>
<td>France (5'132'422 EUR)</td>
<td>(5'005'317)</td>
<td></td>
</tr>
<tr>
<td><strong>SUB TOTAL CURRENT DEFERRED INCOME</strong></td>
<td><strong>(12'412'953)</strong></td>
<td><strong>(6'793'570)</strong></td>
</tr>
</tbody>
</table>

### LONG TERM

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>France (40'721'321 EUR)</td>
<td>(40'104'886)</td>
<td></td>
</tr>
<tr>
<td>UNITAID (12'853'408 USD)</td>
<td>(11'896'452)</td>
<td>(17'589'218)</td>
</tr>
<tr>
<td>Canada (45'000'000 CAD)</td>
<td>(50'688'650)</td>
<td></td>
</tr>
<tr>
<td>SDC</td>
<td></td>
<td>(175'038)</td>
</tr>
<tr>
<td><strong>SUB TOTAL NON-CURRENT DEFERRED INCOME</strong></td>
<td><strong>(82'661'987)</strong></td>
<td><strong>(17'764'276)</strong></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>95'074'939</strong></td>
<td><strong>(24'537'845)</strong></td>
</tr>
</tbody>
</table>

NOTE 10: DONATIONS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNITAID (5'540'694 USD)</td>
<td>5'160'689</td>
<td>6'922'843</td>
</tr>
<tr>
<td>SDC</td>
<td>300'000</td>
<td>552'000</td>
</tr>
<tr>
<td>Government of France (7'645'756 EUR)</td>
<td>7'973'632</td>
<td>14'460'525</td>
</tr>
<tr>
<td>Government of Japan (165'000 USD)</td>
<td>158'867</td>
<td>913'710</td>
</tr>
<tr>
<td>WHO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIZ</td>
<td></td>
<td>288'692</td>
</tr>
<tr>
<td>Gap-f (24'750 USD)</td>
<td>21'820</td>
<td></td>
</tr>
<tr>
<td>Belgium (1'000'000 EUR)</td>
<td>970'538</td>
<td></td>
</tr>
<tr>
<td>Government of Norway (4'352'500 USD)</td>
<td>4'106'680</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>18'982'718</td>
<td>22'849'078</td>
</tr>
</tbody>
</table>

UNITAID

The Medicines Patent Pool Foundation (MPP) was established as an independent legal entity on the 16th July 2010 with the support of UNITAID, which remains MPP’s main donor. Per MPP’s statutes, the majority of MPP’s third party funding (excluding royalty payments, if any) shall come from sources of public and/or non-profit nature.

On the 16th November 2020, MPP and UNITAID signed the 3rd Memorandum Of Understanding granting MPP a maximum amount of USD 34,270,571 for the period January 2021 to December 2025, subject to pre-approval of yearly budgets submitted by MPP.

The donations from UNITAID are restricted to serve the objectives of the Foundation.

SWISS AGENCY FOR COOPERATION AND DEVELOPMENT

On the 10th December 2019, MPP and the FDFA/SDC signed a grant of CHF 1’743’038 for the period January 2020 to December 2022. This grant is co-funded with Unitad (50%/50%) to finance MPP’s expansion activities with co-morbidities.

GOVERNMENT OF JAPAN

On the 19th August 2020, MPP and the Government of Japan, through the World Health Organisation (WHO), signed a Memorandum of Understanding granting MPP a maximum amount of USD 165,000 which was also granted in May 2022 for the implementation period April 2022 to December 2022.

GOVERNMENT OF FRANCE

On the 5th October 2021, the French Government and MPP signed a contract of EUR 5,000,000 to directly fund the activities of MPP to support the mRNA Technology Transfer Programme until December 2025. On the 22nd July 2022, a further contract was signed for EUR 15,000,000 to increase these activities until 2025.
Additionally, the French Government agreed to fund the activities of the Technology Transfer hub sub grantees in South Africa. On the 5th October 2021, MPP signed a contract to secure EUR 8,500,000, on the 22nd July for a further EUR 8,500,000 and then on the 2nd December for a further EUR 30,000,000 for sub grantee activities.

Government of Canada

In 2022 the Canadian government agreed to funding of CAD 45,000,000 for the mRNA Technology Transfer Programme for the period March 2022 to March 2024.

Government of Germany

On 7th February 2022, MPP and the German Agency for International Cooperation (GIZ), through the World Health Organisation (WHO), signed a contract for EUR 1,130,072 for mRNA patent landscaping during the period January 2022 to August 2023.

Government of Norway

USD 4,332,500 for the Technology Transfer Hub in South Africa to be implemented by December 2022.

World Health Organisation (WHO)

On 15th August 2022 MPP signed a contract with the WHO for USD 24,750 for project support to GAP-f to be used by December 2022.

World Health Organisation (Acting on behalf of Government of Belgium)

On 4th October 2022, MPP signed a contract with the WHO (acting on behalf of the Government of Belgium) for EUR 1’000’000 transfer package. This is to support the successful development of technology at the South African mRNA hub and is to be used by 31st December 2022.

Note 11: Net Financial Result

The financial income and costs are the following:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange (loss), net</td>
<td>118’744</td>
<td>(279’464)</td>
</tr>
<tr>
<td>Bank interest income</td>
<td>20’275</td>
<td>5’689</td>
</tr>
<tr>
<td>Others, net</td>
<td>(47’961)</td>
<td>(8’511)</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>91’057</td>
<td>(282’286)</td>
</tr>
</tbody>
</table>

Note 12: Pro-Bono Agreements

The MPP did not receive pro bono legal services this fiscal year (0.- CHF in 2021).

Note 13: Other Information

Remuneration of the Governing Bodies of the Foundation and Management

The members of the Governing Bodies of the Foundation – the Governance Board and the Expert Advisory Group - do not receive any remuneration in respect of their activities within the Foundation. The management of the Foundation is handled by one person. As permitted by Swiss GAAP FER 21.45, the disclosure of the compensation has been waived.

Note 14: Number of Employees

The Foundation had an average of 38.5 employees (FTE) in 2022 (30.3 employees – 2021). Including 5 employees in India.

Note 15: Liabilities from Leasing Contracts

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities from leasing agreement up to one year</td>
<td>293’069</td>
<td>292’799</td>
</tr>
<tr>
<td>Liabilities from leasing agreement from one year to five years</td>
<td>748’566</td>
<td>1’055’960</td>
</tr>
</tbody>
</table>

Note 16: Pension Fund

As of December 31st 2022 the organisation has a liability due to the pension fund amounting to CHF 159’169 (2021: CHF 116’396).

Note 17: Subsequent Events

On 16th March 2023 MPP signed a new contract with the Swiss Development Agency for CHF 1’500’000 (for the period Jan 2023 – Dec 2025) to finance MPP’s expansion activities with co-morbidities. In 2023 this is co-funded by UNITAID.